{
    "items": "245",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds",
            "url": "https://www.cnn.com/2024/04/06/health/wegovy-heart-failure-diabetes/index.html",
            "time_published": "20240406T201500",
            "authors": [
                "Jen Christensen"
            ],
            "summary": "The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to a new study.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/ap24081724017704.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.136934,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.030918",
                    "ticker_sentiment_score": "0.107013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.030918",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.030918",
                    "ticker_sentiment_score": "0.114424",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock",
            "url": "https://www.fool.com/investing/2024/04/06/eli-lillys-wegovy-competitor-is-causing-supply-con/",
            "time_published": "20240406T123000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Things are going exactly as planned for the biotech giant.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771534/physician-talking-to-patient.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.16125,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.415535",
                    "ticker_sentiment_score": "0.140382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.136348",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is it Too Late to Buy Viking Therapeutics Stock?",
            "url": "https://www.fool.com/investing/2024/04/06/is-it-too-late-to-buy-viking-therapeutics-stock/",
            "time_published": "20240406T114500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771592%2Fgettyimages-1389957907.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.231467,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.454511",
                    "ticker_sentiment_score": "0.246101",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.237551",
                    "ticker_sentiment_score": "0.217555",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-pullback-weight-loss-drugs/",
            "time_published": "20240405T163500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/SOTD-4-5-2024NVO.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.21862,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.13511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.187818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.187818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.294962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.373378",
                    "ticker_sentiment_score": "0.138725",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Assessing Novo Nordisk: Insights From 10 Financial Analysts",
            "url": "https://markets.businessinsider.com/news/stocks/assessing-novo-nordisk-insights-from-10-financial-analysts-1033226534",
            "time_published": "20240405T161942",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "10 analysts have expressed a variety of opinions on Novo Nordisk ( NYSE:NVO ) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and ...",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_3.png",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.94762"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.290129,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.349153",
                    "ticker_sentiment_score": "0.120314",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics",
            "url": "https://www.fool.com/investing/2024/04/05/better-booming-biotech-stock-madrigal-vs-viking/",
            "time_published": "20240405T111500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "These businesses should see good times ahead.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770857/standing-pair-of-investors-consider-tablet-and-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.264513,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.099271",
                    "ticker_sentiment_score": "0.103942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.148426",
                    "ticker_sentiment_score": "0.176319",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.029967",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial",
            "url": "https://www.cnbc.com/2024/04/04/drug-similar-to-ozempic-slowed-parkinsons-disease-in-small-trial.html",
            "time_published": "20240404T135639",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The drug, made by Sanofi, is a GLP-1 like Novo Nordisk's blockbuster diabetes injection Ozempic and weight loss counterpart ...",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/104140008-GettyImages-565784959.jpg?v=1712236145&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.043163,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07446",
                    "ticker_sentiment_score": "0.101354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.291471",
                    "ticker_sentiment_score": "0.200327",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics Just Announced More Positive Results: Time to Buy?",
            "url": "https://www.fool.com/investing/2024/04/04/viking-therapeutics-just-announced-more-positive/",
            "time_published": "20240404T131500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The drugmaker isn't losing momentum.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771116/patient-taking-medicine.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.222639,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.742397",
                    "ticker_sentiment_score": "0.366209",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064449",
                    "ticker_sentiment_score": "0.106378",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves",
            "url": "https://www.fool.com/investing/2024/04/04/after-wegovys-approval-to-treat-heart-disease-novo/",
            "time_published": "20240404T113000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771097%2Fdoctor-patient-check-up-blood-pressure-pulse.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.435551,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.179974",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.775706",
                    "ticker_sentiment_score": "0.60297",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Danone CEO downplays threat of weight loss drugs on food producers: 'We see ourselves as extremely complementary'",
            "url": "https://www.cnbc.com/2024/04/04/danone-ceo-downplays-threat-of-weight-loss-drugs-on-food-producers.html",
            "time_published": "20240404T104520",
            "authors": [
                "Karen Gilchrist"
            ],
            "summary": "The CEO of French consumer goods giant Danone downplayed the threat of obesity drugs on its food business, arguing that consumers were likely to turn to healthy products as part of their new regime.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107396671-17122257871712225785-33986335060-1080pnbcnews.jpg?v=1712225786&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.090731,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.090816",
                    "ticker_sentiment_score": "-0.105811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090816",
                    "ticker_sentiment_score": "-0.1327",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Brand-New  ( Good )  Reason to Buy Viking Therapeutics Stock Now",
            "url": "https://www.fool.com/investing/2024/04/04/1-brand-new-good-reason-to-buy-viking-therapeutics/",
            "time_published": "20240404T103000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Its long-term growth potential looks like it's improving, again.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771186/doctor-and-nurse-talk-with-investor.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.166721,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "0.201105",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "-0.038988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Notice convening the Annual General Meeting in BioPorto A/S",
            "url": "https://www.globenewswire.com/news-release/2024/04/04/2857564/0/en/Notice-convening-the-Annual-General-Meeting-in-BioPorto-A-S.html",
            "time_published": "20240404T090700",
            "authors": [
                "BioPorto A/S"
            ],
            "summary": "April 4, 2024Announcement no. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9686d8c-3706-4a6c-b22a-ae722c122c21",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.146644,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HOLX",
                    "relevance_score": "0.024322",
                    "ticker_sentiment_score": "0.035793",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDXH",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.015457",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DGX",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.015457",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXAS",
                    "relevance_score": "0.024322",
                    "ticker_sentiment_score": "0.016974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.035669",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTKB",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.015457",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TTOO",
                    "relevance_score": "0.024322",
                    "ticker_sentiment_score": "0.119451",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNAC",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.009576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMSQF",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.017547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LH",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.015457",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BVNKF",
                    "relevance_score": "0.012162",
                    "ticker_sentiment_score": "0.035669",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?",
            "url": "https://www.fool.com/investing/2024/04/04/could-this-1-detail-help-viking-top-lilly-novo/",
            "time_published": "20240404T085500",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking shares have soared recently on optimism about its program.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771655%2Fgettyimages-1351333930.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.239522,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.302808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.104156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.130001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.302808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Topped the Market Today",
            "url": "https://www.fool.com/investing/2024/04/03/why-eli-lilly-stock-topped-the-market-today/",
            "time_published": "20240403T203102",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "One analyst following the company believes it could grow its revenue meaningfully this year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771731/stethescope-atop-us-currency-and-coins.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.279871,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.549581",
                    "ticker_sentiment_score": "0.361821",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.294093",
                    "ticker_sentiment_score": "0.259711",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co  ( NYSE:LLY ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/markets/equities/24/04/38077966/eli-lilly-struggles-to-keep-pace-with-mounjaro-zepbound-demand-currently-unavailable-on-amazon-p",
            "time_published": "20240403T200742",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-ai.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.033528,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.493442",
                    "ticker_sentiment_score": "-0.157577",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.083065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "-0.18623",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "You can now get Ozempic at Costco - but don't expect big savings",
            "url": "https://www.businessinsider.com/you-can-get-ozempic-at-costco-dont-expect-big-savings-2024-4",
            "time_published": "20240403T181000",
            "authors": [
                "Alex Bitter"
            ],
            "summary": "You can now get Ozempic at Costco, but don't expect big savings. - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.043201,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "0.055579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.658245",
                    "ticker_sentiment_score": "0.085563",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084127",
                    "ticker_sentiment_score": "0.048942",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Digital Realty  ( DLR )  to Host AI Supercomputer in Denmark",
            "url": "https://www.zacks.com/stock/news/2250037/digital-realty-dlr-to-host-ai-supercomputer-in-denmark",
            "time_published": "20240403T174000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Digital Realty (DLR) announces its selection for hosting Nvidia-Powered AI supercomputer at its data center in Denmark.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3f/989.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.250281,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LAMR",
                    "relevance_score": "0.128478",
                    "ticker_sentiment_score": "0.067533",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.668128",
                    "ticker_sentiment_score": "0.312045",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DLR",
                    "relevance_score": "0.128478",
                    "ticker_sentiment_score": "0.096814",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064449",
                    "ticker_sentiment_score": "0.132162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WELL",
                    "relevance_score": "0.128478",
                    "ticker_sentiment_score": "0.067533",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/asia/24/04/38075244/novo-nordisks-popular-diabetes-drug-ozempic-starter-kits-face-extended-shortages-in-germany-faces-bi",
            "time_published": "20240403T173747",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic ( semaglutide ) will not be available in Germany during the second quarter.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_9.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.007237,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "-0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "0.064828",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion",
            "url": "https://www.cnbc.com/2024/04/03/weight-loss-diabetes-drug-ad-spending-tops-1-billion.html",
            "time_published": "20240403T173300",
            "authors": [
                "Annika Kim Constantino",
                "Ashley Capoot"
            ],
            "summary": "Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107393130-1711478516428-gettyimages-930124978-941_30_bsip_015490_058.jpeg?v=1711478620&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.064069,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.035714",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17715",
                    "ticker_sentiment_score": "0.040853",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What To Know About Jiyoutai-China's First Potential Ozempic Challenger",
            "url": "https://www.forbes.com/sites/jamesfarrell/2024/04/03/what-to-know-about-jiyoutai-chinas-first-potential-ozempic-challenger/",
            "time_published": "20240403T163917",
            "authors": [
                "James Farrell"
            ],
            "summary": "A Chinese pharmaceutical company is seeking approval to market Jiyoutai, an alternative to Ozempic that could be the first biosimilar drug to compete with Novo Nordisk's weight-loss and diabetes drugs in China ahead of a potential flood of new obesity medicines in the country-especially as Novo ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/660d85c4ad3df153d7c67a22/0x0.jpg?format=jpg&crop=2152,1211,x0,y108,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.132436,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.216006",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Swedbank Robur Fonder AB",
            "url": "https://www.globenewswire.com/news-release/2024/04/03/2857099/0/en/Major-shareholder-announcement-Swedbank-Robur-Fonder-AB.html",
            "time_published": "20240403T140500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.124283,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia Is Bringing Artificial Intelligence  ( AI )  to the Healthcare Space. Here's How.",
            "url": "https://www.fool.com/investing/2024/04/03/nvidia-is-bringing-artificial-intelligence-ai-to-t/",
            "time_published": "20240403T103000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Nvidia may be known for its semiconductor chips, but the company is making waves in the healthcare space.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771256%2Fgettyimages-1096227322.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.324391,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.383097",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "0.179996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "China develops first biosimilar of globally popular weight loss drug Ozempic; Application submitted for approval",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/china-develops-first-biosimilar-of-globally-popular-weight-loss-drug-ozempic-application-submitted-for-approval/3445129/",
            "time_published": "20240403T102947",
            "authors": [
                "Health Desk"
            ],
            "summary": "China develops first biosimilar of globally popular weight loss drug Ozempic. Application submitted for approval The Financial Express ...",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/04/vitamins-g81bff71f1_1920.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.26041,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.277574",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras - Costco Wholesale  ( NASDAQ:COST ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/04/38063177/costco-long-known-for-rotisserie-chicken-and-hot-dogs-counters-junk-food-with-weight-loss-plan-to-he",
            "time_published": "20240403T072117",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Costco Wholesale Corporation COST has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/CostCo_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.233351,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.111226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.308891",
                    "ticker_sentiment_score": "0.165273",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.104601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.009183",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Costco launches weight loss program for members",
            "url": "https://www.foxbusiness.com/lifestyle/costco-launches-weight-loss-program-for-members",
            "time_published": "20240402T230800",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Costco is jumping into the weight loss game by giving members access to sought-after medications such as those made by pharmaceutical giants Eli Lilly and Novo Nordisk.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/5a9b6e77-4a51-4171-8fc0-d58c535167f5/b486510e-817e-4174-89fb-58c80b1307b2/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.284172,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "COST",
                    "relevance_score": "0.453099",
                    "ticker_sentiment_score": "0.352232",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.095899",
                    "ticker_sentiment_score": "0.004319",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "TraceLink Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024",
            "url": "https://www.prnewswire.com/news-releases/tracelink-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2024-302106259.html",
            "time_published": "20240402T190700",
            "authors": [
                "Tracelink",
                "Inc."
            ],
            "summary": "TraceLink joins the ranks of Nvidia, YouTube, OpenAI, Novo Nordisk and more BOSTON , April 2, 2024 /PRNewswire/ -- TraceLink has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024.",
            "banner_image": "https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.506363,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "TraceLink Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024",
            "url": "https://www.newswire.ca/news-releases/tracelink-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-of-2024-892829818.html",
            "time_published": "20240402T190700",
            "authors": [
                "Inc.",
                "Tracelink"
            ],
            "summary": "TraceLink joins the ranks of Nvidia, YouTube, OpenAI, Novo Nordisk and more BOSTON , April 2, 2024 /CNW/ -- TraceLink has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024. This year's list shines a spotlight on businesses that are shaping their ...",
            "banner_image": "https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.506363,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca  ( NASDAQ:AZN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/04/38055367/astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in",
            "time_published": "20240402T185401",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AstraZeneca-HQ-in-Cambridge-UK_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.214279,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.093594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.111146",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.727604",
                    "ticker_sentiment_score": "0.189804",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.093594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.285526",
                    "ticker_sentiment_score": "-0.124969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38055169/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-le",
            "time_published": "20240402T184150",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Citi Research has increased the price target for Eli Lilly And Co LLY, reflecting increased anticipated risk-adjusted peak sales for the company's oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.109662,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.72844",
                    "ticker_sentiment_score": "0.192565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362505",
                    "ticker_sentiment_score": "0.194362",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "0.120995",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience-1033215940",
            "time_published": "20240402T160915",
            "authors": [
                "Surbhi Jain"
            ],
            "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's ( NYSE:LLY ) strategic positioning and technical resilience present a compelling investment opportunity.",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                }
            ],
            "overall_sentiment_score": 0.231119,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.640349",
                    "ticker_sentiment_score": "0.379462",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.008505",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38051329/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience",
            "time_published": "20240402T153943",
            "authors": [
                "Surbhi Jain"
            ],
            "summary": "Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's LLY strategic positioning and technical resilience present a compelling investment opportunity. Zepbound boasts impressive weight-loss efficacy in ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                }
            ],
            "overall_sentiment_score": 0.281184,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.575407",
                    "ticker_sentiment_score": "0.435661",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.012024",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Smart Money Is Betting Big In NVO Options - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/04/38050669/smart-money-is-betting-big-in-nvo-options",
            "time_published": "20240402T151636",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.111382,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.778376",
                    "ticker_sentiment_score": "0.259948",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/24/04/38050339/diabetes-drug-made-for-under-5-costs-americans-1-000-drawing-comparisons-to-martin-shrikeli-while-ju",
            "time_published": "20240402T150613",
            "authors": [
                "Caleb Naysmith"
            ],
            "summary": "The stock of Danish drugmaker Novo Nordisk NVO has been on a tear, up over 400% in the past five years. It's been so successful that its nearly $500 billion market cap exceeds Denmark's entire gross domestic product ( GDP ) , where the company is based.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/West-Bangal--India---April-20--2022--Nov_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.149743,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.31899",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RDDT",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.214467",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.31899",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.183234",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Analysts Think Novo Nordisk  ( NVO )  Is a Good Investment: Is It?",
            "url": "https://www.zacks.com/stock/news/2249062/wall-street-analysts-think-novo-nordisk-nvo-is-a-good-investment-is-it",
            "time_published": "20240402T133009",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.280264,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.357049",
                    "ticker_sentiment_score": "0.165608",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/04/02/2855769/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240402T105600",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 2 April 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.12545,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.200514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy Eli Lilly Stock?",
            "url": "https://www.fool.com/investing/2024/04/02/is-it-too-late-to-buy-eli-lilly-stock/",
            "time_published": "20240402T091000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "There's more to the Lilly story than just excellence in one treatment area.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771415%2Fgettyimages-613345556.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.25364,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.50287",
                    "ticker_sentiment_score": "0.312039",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.190076",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.190076",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.10048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "-0.10048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Novo Nordisk  ( NVO )  Fell More Than Broader Market",
            "url": "https://www.zacks.com/stock/news/2248701/heres-why-novo-nordisk-nvo-fell-more-than-broader-market",
            "time_published": "20240401T215020",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.16253,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.541943",
                    "ticker_sentiment_score": "0.161052",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus",
            "url": "https://www.zacks.com/stock/news/2248253/take-the-zacks-approach-to-beat-the-market-nvidia-dell-modine-in-focus",
            "time_published": "20240401T120300",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3e/1190.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                }
            ],
            "overall_sentiment_score": 0.205205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KOD",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.295886",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.061306",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SE",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.061306",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOD",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.313089",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.102303",
                    "ticker_sentiment_score": "0.108055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.101314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.061331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSCO",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.061331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.295886",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.034185",
                    "ticker_sentiment_score": "0.13967",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.034185",
                    "ticker_sentiment_score": "0.13967",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
            "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
            "time_published": "20240401T083000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.24052,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "0.180009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125679",
                    "ticker_sentiment_score": "0.255601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCA",
                    "relevance_score": "0.248259",
                    "ticker_sentiment_score": "0.115038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.28535",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.167032",
                    "ticker_sentiment_score": "0.306284",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.167032",
                    "ticker_sentiment_score": "0.286408",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.134207",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.207928",
                    "ticker_sentiment_score": "0.100054",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk the Best Healthcare Stock for You?",
            "url": "https://www.fool.com/investing/2024/03/31/is-novo-nordisk-the-best-healthcare-stock-for-you/",
            "time_published": "20240331T221400",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Novo Nordisk has been a hot buy in recent years, but in the long run, the stock can still go a whole lot higher.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770407/doctor-meeting-a-salesperson.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.327002,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.022452",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.631282",
                    "ticker_sentiment_score": "0.438626",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.153542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.153542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The 'Oatzempic Challenge' On TikTok: Here's What You Need To Know",
            "url": "https://www.forbes.com/sites/brucelee/2024/03/31/what-is-the-oatzempic-challenge-on-tiktok-what-you-need-to-know/",
            "time_published": "20240331T160917",
            "authors": [
                "Bruce Y. Lee"
            ],
            "summary": "Talk about sowing some wild oats. TikTokers have been adding the word \"oat\" to Ozempic to name a liquid concoction of oats, water, and lime juice. They've been calling this drink \"Oatzempic,\" even though there's no Ozempic medication in it.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66094400a070a10f94de3aa5/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.045747,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.043289",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.",
            "url": "https://www.fool.com/investing/2024/03/31/prediction-pfizer-wont-acquire-viking-therapeutics/",
            "time_published": "20240331T133100",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Viking Therapeutics may be the next company to enter the red-hot weight loss space.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770764%2Fmedical-sales-doctor-hospital-equipment.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072326,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.058759",
                    "ticker_sentiment_score": "0.053174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.175009",
                    "ticker_sentiment_score": "0.176168",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.6979",
                    "ticker_sentiment_score": "0.038482",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock",
            "url": "https://www.fool.com/investing/2024/03/31/diversifying-into-this-key-market-is-1-more-reason/",
            "time_published": "20240331T121500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The semaglutide maker just announced a strategic acquisition that will be a green flag for its future value.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770859/novo_nordisk_building_with_logo_nvo.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.233388,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.370602",
                    "ticker_sentiment_score": "0.239706",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Could weight-loss drugs eat the world?",
            "url": "https://www.economist.com/science-and-technology/2024/03/30/could-weight-loss-drugs-eat-the-world",
            "time_published": "20240330T155906",
            "authors": [
                "The Economist"
            ],
            "summary": "T monster is a poisonous North American lizard that measures around 50 centimetres and sports a distinctive coat of black and orange scales.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240406_STC135.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.002444,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.021542",
                    "ticker_sentiment_score": "-0.053332",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bernie Sanders Slams 'Outrageous' Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/03/38012469/bernie-sanders-slams-outrageous-prices-of-miracle-weight-loss-drug-ozempic-mulls-meeting-with-novo-n",
            "time_published": "20240330T081912",
            "authors": [
                "Rounak Jain"
            ],
            "summary": "Sen. Bernie Sanders ( I-Vt. ) has taken a stand against the \"outrageous\" prices of diabetes drug Ozempic by Novo Nordisk NVO. He is considering hearings on the issue and is seeking a meeting with the company's CEO to discuss reducing the drug's price.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bernie-Sanders-Ozempic.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.004822,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28664",
                    "ticker_sentiment_score": "-0.154347",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "0.277332",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A new Ozempic rival helps patients lose fat, but keep their muscle - the holy grail for a weight-loss drug",
            "url": "https://www.businessinsider.com/new-weight-loss-drug-mimics-exercise-with-a-shot-2024-3",
            "time_published": "20240329T163800",
            "authors": [
                "Hilary Brueck"
            ],
            "summary": "New GLP-1 weight loss drug mimics effects of exercise with a shot - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.009832,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.293506",
                    "ticker_sentiment_score": "-0.008969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "-0.147032",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  is a Top Stock for the Long-Term",
            "url": "https://www.zacks.com/stock/news/2247877/why-novo-nordisk-nvo-is-a-top-stock-for-the-long-term",
            "time_published": "20240329T133005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default43.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99489"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.303129,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.190667",
                    "ticker_sentiment_score": "0.217528",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy Viking Therapeutics Stock?",
            "url": "https://www.fool.com/investing/2024/03/29/is-it-too-late-to-buy-viking-therapeutics-stock/",
            "time_published": "20240329T131500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Shares of Viking Therapeutics have skyrocketed more than 350% this year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770408/a-person-looking-at-a-chart-on-their-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.258859,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.200743",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "-0.095693",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.027845",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals",
            "url": "https://www.fool.com/investing/2024/03/29/better-buy-viking-therapeutics-vs-madrigal-pharma/",
            "time_published": "20240329T130000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Both stocks are pretty risky, but one of them more so than the other.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770453/elderly-person-sitting-on-a-bed.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.214454,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "0.149838",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "0.110527",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.03591",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?",
            "url": "https://www.fool.com/investing/2024/03/29/is-this-healthcare-stock-a-screaming-buy-after-sco/",
            "time_published": "20240329T084300",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?",
            "banner_image": "https://g.foolcdn.com/editorial/images/770399/a-doctor-looking-at-a-tablet-with-another-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.110564,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "-0.083937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.070663",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1? - SPDR S&P 500  ( ARCA:SPY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/38001174/bitcoin-vs-gold-vs-spy-which-asset-class-wouldve-given-best-returns-on-1000-investm",
            "time_published": "20240329T062433",
            "authors": [
                "Shanthi Rexaline"
            ],
            "summary": "The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried about the sustainability of the uptrend. How long will the party last? What are the risks involved in investing in an overbought market?",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bitcoin-Vs-Gold-Vs-Stock-Market.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.181178,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.141153",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.206359",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.138869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.206359",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.222427",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CEG",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MKTX",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.141153",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.069407",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.17926",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MU",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.095771",
                    "ticker_sentiment_score": "0.187694",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TOL",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.1196",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.222427",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "OPRA",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.174244",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DECK",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHTR",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.141153",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALIZF",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.159481",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.1196",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "0.115863",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.318198",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst - Scholar Rock Holding  ( NASDAQ:SRRK ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37992240/scholar-rock-is-a-potential-m-a-target-its-exploration-of-obesity-market-garners-in",
            "time_published": "20240328T184242",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Raymond James has initiated coverage on Scholar Rock Holding SRRK, supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.285533,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "0.037784",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRRK",
                    "relevance_score": "0.516656",
                    "ticker_sentiment_score": "0.354955",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "2 Top Biotech Buyout Candidates",
            "url": "https://www.zacks.com/commentary/2247682/2-top-biotech-buyout-candidates",
            "time_published": "20240328T175500",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.182342,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.277748",
                    "ticker_sentiment_score": "0.202168",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.305633",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.136246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.477704",
                    "ticker_sentiment_score": "0.429519",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.04075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.330286",
                    "ticker_sentiment_score": "0.29467",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-",
            "time_published": "20240328T165436",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A recent study suggests that despite Novo Nordisk A/S's NVO high monthly charge of close to $1,000 for its blockbuster diabetes drug Ozempic ( semaglutide ) in the U.S., it could be produced for less than $5 a month.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.082894,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.095642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ELV",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.095642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.446742",
                    "ticker_sentiment_score": "0.259557",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Fungicides Market Size is projected to reach USD 23,393.85 million by 2031, growing at a CAGR of 4.6%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37987844/fungicides-market-size-is-projected-to-reach-usd-23-393-85-million-by-2031-growing-at-a-cagr-of-4-",
            "time_published": "20240328T155500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, March 28, 2024 ( GLOBE NEWSWIRE ) -- Modern crop protection against fungal diseases must include fungicides. Due to changes in farming practices and technological advancements, farmers are now encouraged to practice effective pest management.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.163042,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTVA",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "0.093147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "-0.061172",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "-0.061172",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "-0.061172",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EVGN",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "0.196528",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NUFMF",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "-0.061172",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOMMF",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "-0.061172",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Shows Breadth As Leaders Take A Breath: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-breadth-leaders-take-a-breath/",
            "time_published": "20240328T145250",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "The stock market rally was mixed in a holiday-shortened week. The Nasdaq fell modestly while the Russell 2000 rose solidly. Many AI and other growth leaders suffered solid to sharp losses. DraftKings ( DKNG ) fell sharply as the NCAA moved to ban special prop bets following claims regarding a pro ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-BullPortrait-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.04615,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.187949",
                    "ticker_sentiment_score": "-0.020614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.028481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.072062",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "-0.051824",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "-0.021015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FLUT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.011055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.157073",
                    "ticker_sentiment_score": "-0.027108",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.125953",
                    "ticker_sentiment_score": "-0.037416",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.157073",
                    "ticker_sentiment_score": "0.012638",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NCLH",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.042335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "0.092167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.01012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "-0.042335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.268541",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.125953",
                    "ticker_sentiment_score": "0.08374",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Insurance Coverage For Weight Loss Drugs - Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk's Successful Wegovy For Certain Patients - CVS Health  ( NYSE:CVS ) , Novo Nordisk  ( NYSE:NVO ) , Elevance Health  ( NYSE:ELV ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37984877/insurance-coverage-for-weight-loss-drugs-elevance-cvs-health-become-first-to-extend-coverage-to-n",
            "time_published": "20240328T142538",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Some major U.S. health insurers, including CVS Health Inc CVS, Elevance Health Inc ELV, and Kaiser Permanente will start reimbursing for Novo Nordisk A/S's NVO Wegovy, a popular anti-obesity drug, for specific individuals on Medicare who have heart-related conditions.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_8.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.184548,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.238133",
                    "ticker_sentiment_score": "0.129405",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.160099",
                    "ticker_sentiment_score": "0.091024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ELV",
                    "relevance_score": "0.238133",
                    "ticker_sentiment_score": "0.104597",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.313817",
                    "ticker_sentiment_score": "0.168009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What the Options Market Tells Us About Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37984146/what-the-options-market-tells-us-about-novo-nordisk",
            "time_published": "20240328T140108",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.178954,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.682689",
                    "ticker_sentiment_score": "0.242827",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs",
            "url": "https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvos-new-mas-fda-nod-to-jnj-mrk-pah-drugs",
            "time_published": "20240328T135000",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.224037,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LABP",
                    "relevance_score": "0.120632",
                    "ticker_sentiment_score": "0.093927",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.238523",
                    "ticker_sentiment_score": "0.213891",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.120632",
                    "ticker_sentiment_score": "0.069053",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.387075",
                    "ticker_sentiment_score": "0.120962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.080593",
                    "ticker_sentiment_score": "-0.06506",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update",
            "url": "https://www.globenewswire.com/news-release/2024/03/28/2854087/0/en/Omega-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Strategic-Update.html",
            "time_published": "20240328T131500",
            "authors": [
                "Omega Therapeutics"
            ],
            "summary": "CAMBRIDGE, Mass., March 28, 2024 ( GLOBE NEWSWIRE ) -- Omega Therapeutics, Inc. ( Nasdaq: OMGA ) ( \"Omega\" ) , a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the fourth quarter and ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/4428645b-4edb-49ba-af06-8f9ac7dc4c11",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.190539,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.070053",
                    "ticker_sentiment_score": "0.126948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "0.099988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Daily: Why Disney's Rising Stock Still Has Room To Run",
            "url": "https://www.forbes.com/sites/daniellechemtob/2024/03/28/forbes-daily-why-disneys-rising-stock-still-has-room-to-run/",
            "time_published": "20240328T121944",
            "authors": [
                "Danielle Chemtob"
            ],
            "summary": "Forbes Daily: Positive outlook sees Disney stock price continue to rise Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66055d2027c92c8a1fecd2c1/0x0.jpg?format=jpg&crop=1515,852,x0,y97,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.112392,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APG",
                    "relevance_score": "0.023464",
                    "ticker_sentiment_score": "0.102975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.023464",
                    "ticker_sentiment_score": "0.099788",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.046907",
                    "ticker_sentiment_score": "-0.014915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFTBF",
                    "relevance_score": "0.023464",
                    "ticker_sentiment_score": "0.102975",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?",
            "url": "https://www.investors.com/news/technology/alzheimers-disease-treatments-eli-lilly-donanemab-amyloid-beta/",
            "time_published": "20240328T120021",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/TECHpic-brain-040124-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.036018,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "-0.071189",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALEC",
                    "relevance_score": "0.13414",
                    "ticker_sentiment_score": "0.151708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INMB",
                    "relevance_score": "0.02695",
                    "ticker_sentiment_score": "-0.070252",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.264515",
                    "ticker_sentiment_score": "-0.024517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "0.09074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.041674",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "-0.025612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.05387",
                    "ticker_sentiment_score": "-0.068762",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prediction: This Will Be the Next \"Magnificent Seven\" Stock",
            "url": "https://www.fool.com/investing/2024/03/28/this-will-be-next-magnificent-seven-stock/",
            "time_published": "20240328T105000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "This particular company's growth is set to take off...",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770699%2Fgettyimages-1191849990.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.336254,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.149346",
                    "ticker_sentiment_score": "0.313833",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "-0.018311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.191248",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "-0.063004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.653512",
                    "ticker_sentiment_score": "0.469235",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "-0.063004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "0.140213",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV",
            "url": "https://www.forbes.com/sites/katiejennings/2024/03/27/innovationrx-base-editing-pioneer-nicole-gaudelli-joins-gv/",
            "time_published": "20240327T215849",
            "authors": [
                "Katie Jennings"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/660494100df8c256fcaaaf8d/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.166242,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.109945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LABP",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.103057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.063744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.187223",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.103057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NMTC",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.071685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.103057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "-0.124735",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.171285",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy",
            "url": "https://www.forbes.com/sites/saradorn/2024/03/27/bernie-sanders-calls-on-novo-nordisk-to-lower-cost-of-ozempic-and-wegovy/",
            "time_published": "20240327T211855",
            "authors": [
                "Sara Dorn"
            ],
            "summary": "Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the \"outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66048cd417ea5d90971467a4/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.055049,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "0.052093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "-0.071817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.053135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.053135",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart",
            "url": "https://www.cnbc.com/2024/03/27/altimmune-weight-loss-drug-minimized-muscle-mass-loss-in-trial.html",
            "time_published": "20240327T183036",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107393750-1711561383116-gettyimages-88296329-ti0300206.jpeg?v=1711561428&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.101546,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.357636",
                    "ticker_sentiment_score": "-0.070213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.049847",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Is The Market Feeling About Novo Nordisk? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/short-sellers/24/03/37967278/how-is-the-market-feeling-about-novo-nordisk",
            "time_published": "20240327T181521",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has fallen 38.64% since its last report. The company recently reported that it has 4.67 million shares sold short, which is 0.27% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.262256,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.209365",
                    "ticker_sentiment_score": "0.079385",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests",
            "url": "https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html",
            "time_published": "20240327T165538",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107393000-17114709242023-11-18t105712z_413187213_rc2p34a9p2x4_rtrmadp_0_health-obesity-ozempic.jpeg?v=1711470985&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.044852,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "-0.052665",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking  ( VKTX )  Up 17% on Encouraging Oral Obesity Drug Data",
            "url": "https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data",
            "time_published": "20240327T164200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.163942,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338913",
                    "ticker_sentiment_score": "0.3268",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.245835",
                    "ticker_sentiment_score": "0.1314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.197816",
                    "ticker_sentiment_score": "0.182347",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.292922",
                    "ticker_sentiment_score": "0.310708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-weight-loss-drugs-viking-therapeutics-novo-nordisk/",
            "time_published": "20240327T162253",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-27-2024LLY.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.189317,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.550532",
                    "ticker_sentiment_score": "0.3418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "-0.032259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVCR",
                    "relevance_score": "0.06697",
                    "ticker_sentiment_score": "0.108936",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.030653",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency",
            "url": "https://www.globenewswire.com/news-release/2024/03/27/2853131/0/en/Aeterna-Zentaris-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Announces-Completion-of-Enrollment-in-Ongoing-Pivotal-DETECT-Trial-for-the-Diagnosis-of-Childhood-O.html",
            "time_published": "20240327T120500",
            "authors": [
                "Aeterna Zentaris Inc"
            ],
            "summary": "- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/60b408af-6a44-4c70-81cb-be15cb47b211",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998663"
                }
            ],
            "overall_sentiment_score": 0.170696,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CURN",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.067632",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036504",
                    "ticker_sentiment_score": "0.081976",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AEZS",
                    "relevance_score": "0.109206",
                    "ticker_sentiment_score": "0.084109",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Ozempic And Mounjaro Rivals Won't Topple Drugmakers Novo Nordisk And Eli Lilly Anytime Soon",
            "url": "https://www.forbes.com/sites/roberthart/2024/03/27/heres-why-ozempic-and-mounjaro-rivals-wont-topple-weight-loss-drugmakers-novo-nordisk-and-eli-lilly-anytime-soon/",
            "time_published": "20240327T102646",
            "authors": [
                "Robert Hart"
            ],
            "summary": "The pharmaceutical industry is hooked on weight loss drugs, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6603f16dbbc33a06bbb62c7d/0x0.jpg?format=jpg&crop=3329,1871,x0,y173,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.221949,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.058617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TERN",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.058617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.160953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.058617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.069875",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "BlackRock's Fink Says Capital Markets Can Solve the Retirement Crisis",
            "url": "https://www.barrons.com/amp/articles/blackrocks-fink-retirement-crisis-d2d7654b",
            "time_published": "20240326T212200",
            "authors": [
                "Bill Alpert"
            ],
            "summary": "BlackRock CEO Larry Fink wants to recreate some of the retirement safety net our parents had. In his annual letter to BlackRock shareholders, chief executive Larry Fink talks longingly about his parents' retirement. They invested. They had a pension. They had Social Security. It was enough.",
            "banner_image": "https://images.barrons.com/im-23431344/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.095435,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.48724",
                    "ticker_sentiment_score": "0.220022",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.140967",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients",
            "url": "https://www.cnbc.com/2024/03/26/healthy-returns-drugmakers-are-capping-inhaler-prices-at-35.html",
            "time_published": "20240326T185052",
            "authors": [
                "Annika Kim Constantino",
                "Ashley Capoot"
            ],
            "summary": "Three drugmakers are capping out-of-pocket costs for their inhalers. Meanwhile, many digital diabetes management tools aren't all they're cracked up to be.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/105649172-1545937328446gettyimages-911340738.jpeg?v=1710452648&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.096806,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DRIO",
                    "relevance_score": "0.085731",
                    "ticker_sentiment_score": "0.017614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028626",
                    "ticker_sentiment_score": "-0.090669",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.028626",
                    "ticker_sentiment_score": "-0.090669",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.",
            "url": "https://www.investors.com/news/technology/dexcom-shows-market-leadership-with-jump-to-85-rs-rating/",
            "time_published": "20240326T175600",
            "authors": [
                "JAMES DETAR",
                "INVESTOR'S BUSINESS DAILY",
                "Investor's Business Daily"
            ],
            "summary": "Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-Diabetes-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                }
            ],
            "overall_sentiment_score": 0.241901,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.180181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.196877",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.63935",
                    "ticker_sentiment_score": "0.28814",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.180181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven  ( NYSE:BHVN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff",
            "time_published": "20240326T174838",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072644,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.120107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "0.136685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.239247",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37939801/heres-how-much-1000-invested-in-novo-nordisk-10-years-ago-would-be-worth-today",
            "time_published": "20240326T160020",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.32% on an annualized basis producing an average annual return of 19.04%. Currently, Novo Nordisk has a market capitalization of $580.63 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.238974,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.9545",
                    "ticker_sentiment_score": "0.384186",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Buy Cardior to Boost Heart Disease Pipeline",
            "url": "https://www.zacks.com/stock/news/2246132/novo-nordisk-nvo-to-buy-cardior-to-boost-heart-disease-pipeline",
            "time_published": "20240326T145600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.203441,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.316439",
                    "ticker_sentiment_score": "0.292072",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.316439",
                    "ticker_sentiment_score": "0.248733",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?",
            "url": "https://www.fool.com/investing/2024/03/26/novo-nordisk-and-nvidia-just-partnered-on-ai-is-th/",
            "time_published": "20240326T143500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Their joint project is cutting-edge, but it won't pay off immediately.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770342/novo_nordisk_flag_with_logo_nvo.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.25856,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.272181",
                    "ticker_sentiment_score": "0.265685",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.513606",
                    "ticker_sentiment_score": "0.283142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Awaits Consumer Confidence Data",
            "url": "https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data",
            "time_published": "20240326T142100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.097535,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.069557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "0.080175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.069557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.039322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "-0.176937",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics: Buy, Sell, or Hold?",
            "url": "https://www.fool.com/investing/2024/03/26/viking-therapeutics-buy-sell-or-hold/",
            "time_published": "20240326T140700",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It has a promising candidate and plenty of cash in hand.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767479/doctor-talks-to-patient-while-holding-pill-bottle.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.124507,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.201105",
                    "ticker_sentiment_score": "0.103466",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.037853",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock",
            "url": "https://www.fool.com/investing/2024/03/26/heres-1-huge-new-reason-to-buy-madrigal-pharmaceut/",
            "time_published": "20240326T135300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This biotech just got clearance to dive into a deep ocean of a market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770319/lab-scientist-beaker.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.235629,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.128478",
                    "ticker_sentiment_score": "0.286187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.064449",
                    "ticker_sentiment_score": "-0.029086",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064449",
                    "ticker_sentiment_score": "-0.029086",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days",
            "url": "https://www.investors.com/news/technology/viking-stock-weight-loss-drug-zepbound-wegovy/",
            "time_published": "20240326T130240",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-drugTest-09-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.033581,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "-0.104446",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "-0.187987",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.310843",
                    "ticker_sentiment_score": "-0.315044",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "-0.152404",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NKTX",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "-0.104446",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics stock jumps 15% on promising weight loss pill data",
            "url": "https://www.cnbc.com/2024/03/26/viking-therapeutics-weight-loss-pill-shows-positive-study-results.html",
            "time_published": "20240326T130019",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107392775-1711455744882-gettyimages-1397964265-img_1212.jpeg?v=1711455759&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.069094",
                    "ticker_sentiment_score": "0.083921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069094",
                    "ticker_sentiment_score": "0.11344",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Vanguard International Dividend Appreciation ETF  ( VIGI )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2245787/is-vanguard-international-dividend-appreciation-etf-vigi-a-strong-etf-right-now",
            "time_published": "20240326T102008",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default213.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                }
            ],
            "overall_sentiment_score": 0.26287,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.263214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SAP",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.074847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.066",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?",
            "url": "https://www.fool.com/investing/2024/03/26/best-stock-eli-lilly-novo-nordisk-viking/",
            "time_published": "20240326T095100",
            "authors": [
                "Keith Speights"
            ],
            "summary": "All three of these high-flying stocks could have more room to run.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770468/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.192686,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.28387",
                    "ticker_sentiment_score": "0.288063",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.191549",
                    "ticker_sentiment_score": "0.1832",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.048327",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.372216",
                    "ticker_sentiment_score": "0.150081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Set to Post Fifth Winning Month Amid Volatility",
            "url": "https://www.zacks.com/stock/news/2245743/wall-street-set-to-post-fifth-winning-month-amid-volatility",
            "time_published": "20240326T063300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wall Street is likely to record the fifth consecutive winning month despite volatility.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d3/848.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.099917,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.072406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.248682",
                    "ticker_sentiment_score": "0.08021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.072406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.039322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "-0.176937",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Why the Market Dipped But Novo Nordisk  ( NVO )  Gained Today",
            "url": "https://www.zacks.com/stock/news/2245691/why-the-market-dipped-but-novo-nordisk-nvo-gained-today",
            "time_published": "20240325T215018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default20.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.169975,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.526455",
                    "ticker_sentiment_score": "0.229922",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Looking At Novo Nordisk's Recent Unusual Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37921454/looking-at-novo-nordisks-recent-unusual-options-activity",
            "time_published": "20240325T191612",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 26 unusual trades. Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.151592,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.674691",
                    "ticker_sentiment_score": "0.15597",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market",
            "url": "https://www.fool.com/investing/2024/03/25/uncovering-hidden-gems-1-ai-powered-healthcare/",
            "time_published": "20240325T130700",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Artificial intelligence (AI) could play a big role in medical breakthroughs.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770175%2Fgettyimages-1316753802.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.411952,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.070039",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.49084",
                    "ticker_sentiment_score": "0.50428",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SFSVF",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.070039",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In' - ARM Holdings  ( NASDAQ:ARM ) , Comstock Resources  ( NYSE:CRK ) ",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37908125/cramer-isnt-knocking-this-pharma-firm-anymore-as-a-matter-of-fact-im-going-in",
            "time_published": "20240325T130549",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "Raymond James Financial, Inc. RJF is now valued more highly than JPMorgan Chase & Co. JPM, according to Jim Cramer. \"So, I'm going to have to say, it's too late, we missed it,\" he said. \"Let's find the next one.\"",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/25/jim-cramer2.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.18831,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SOUN",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "-0.132106",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "U",
                    "relevance_score": "0.224383",
                    "ticker_sentiment_score": "0.093302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27838",
                    "ticker_sentiment_score": "0.285327",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MZDAF",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.073927",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.090636",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.105025",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRK",
                    "relevance_score": "0.224383",
                    "ticker_sentiment_score": "0.298063",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.224383",
                    "ticker_sentiment_score": "-0.029968",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.27838",
                    "ticker_sentiment_score": "0.160676",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RJF",
                    "relevance_score": "0.224383",
                    "ticker_sentiment_score": "0.109671",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/03/25/2851536/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240325T115800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 25 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.127925,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.800656",
                    "ticker_sentiment_score": "0.20564",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Council Post: What's Driving Big Pharma's Recent Market Performance?",
            "url": "https://www.forbes.com/sites/forbesfinancecouncil/2024/03/25/whats-driving-big-pharmas-recent-market-performance/",
            "time_published": "20240325T110000",
            "authors": [
                "Dmitry Reykhart"
            ],
            "summary": "What's Driving Big Pharma's Recent Market Performance? Forbes ...",
            "banner_image": "https://blogs-images.forbes.com/assets/images/avatars/blog-4409_400_7bca6d487f6cc72cdf2f893001e4a3c2.jpg",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.105649,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "0.030387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.106227",
                    "ticker_sentiment_score": "0.092964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.0289",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "0.019247",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "-0.124669",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "0.034965",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.106227",
                    "ticker_sentiment_score": "0.026215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.0289",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Eli Lilly May Finally Have Some Real Competition",
            "url": "https://www.fool.com/investing/2024/03/25/novo-nordisk-and-eli-lilly-may-finally-have-some-r/",
            "time_published": "20240325T102500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769906%2Fgettyimages-1346675569.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.27397,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.319725",
                    "ticker_sentiment_score": "0.210402",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.319725",
                    "ticker_sentiment_score": "0.210402",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.353895",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "EQS-News: SYNLAB delivers robust performance in FY 2023",
            "url": "https://markets.businessinsider.com/news/stocks/eqs-news-synlab-delivers-robust-performance-in-fy-2023-1033191685",
            "time_published": "20240325T060005",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "EQS-News: SYNLAB delivers robust performance in FY ...",
            "banner_image": "https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&amp;application_id=1865695&amp;application_name=news&amp;site_id=smarthouse",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999864"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.233756,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.017219",
                    "ticker_sentiment_score": "-0.042372",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Viking Therapeutics Stock a Millionaire Maker?",
            "url": "https://www.fool.com/investing/2024/03/24/is-viking-therapeutics-stock-a-millionaire-maker/",
            "time_published": "20240324T131500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Viking Therapeutics has become one of the hottest healthcare stocks of 2024.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769788/doctor-discussing-a-report-with-people.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                }
            ],
            "overall_sentiment_score": 0.154899,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.277748",
                    "ticker_sentiment_score": "0.256922",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "0.065341",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen wants in on the booming weight loss drug market - and it's taking a different approach",
            "url": "https://www.cnbc.com/2024/03/24/amgen-aims-to-enter-weight-loss-drug-market-with-a-new-approach.html",
            "time_published": "20240324T120002",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107368557-17069062502023-12-13t123425z_1803569422_rc26v4aidh6r_rtrmadp_0_health-obesity-telehealth.jpeg?v=1706906310&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.047954,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.045439",
                    "ticker_sentiment_score": "0.078621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "0.126845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.135729",
                    "ticker_sentiment_score": "0.139189",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "-0.008103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.022729",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's how much people are willing to spend on weight loss drugs, according to a new survey",
            "url": "https://www.cnbc.com/2024/03/23/weight-loss-drug-cost-how-much-people-are-willing-to-spend.html",
            "time_published": "20240323T110001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others - and it's strongly correlated to their annual income.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107378879-1709042048229-gettyimages-1771210816-europapress_5551055_person_using_ozempic_november_2023_in_ma.jpeg?v=1709042239&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.045401,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.039596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "0.082633",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.137898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.05653",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Where Will Viking Therapeutics Stock Be in 10 Years?",
            "url": "https://www.fool.com/investing/2024/03/23/where-will-viking-therapeutics-stock-be-in-10-year/",
            "time_published": "20240323T095300",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Viking's future appears to be very promising, but market dynamics can change.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769981/scientist-looking-through-microscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.171648,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.241962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.383905",
                    "ticker_sentiment_score": "0.105073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.241962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will Pfizer Be a Trillion-Dollar Stock by 2035?",
            "url": "https://www.fool.com/investing/2024/03/23/will-pfizer-be-a-trillion-dollar-stock-by-2035/",
            "time_published": "20240323T083000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769917/scientists-in-a-lab-monitor-microscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.124269,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.069065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.069065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.596433",
                    "ticker_sentiment_score": "0.281024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How Are Obesity Drugs And Nvidia Related? Success Of Ozempic, Wegovy Propels Novo Nordisk Foundation To Fund Nvidia-Powered AI Supercomputer For Faster Drug Development - NVIDIA  ( NASDAQ:NVDA ) , Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37896717/how-are-obesity-drugs-and-nvidia-related-success-of-ozempic-wegovy-propels-novo-nordisk-foundatio",
            "time_published": "20240322T172900",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO, the maker of popular diabetes and weight loss drugs like Ozempic and Wegovy, is delving into artificial intelligence. Backed by the Novo Nordisk Foundation, Eviden, a French computing company, is set to construct a supercomputer leveraging Nvidia Corp's NVDA AI technology.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-Insulin-Injection-Pen-Or-Insulin_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.385283,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.095699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.463125",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.36009",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.720339",
                    "ticker_sentiment_score": "0.596174",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
            "time_published": "20240322T161800",
            "authors": [],
            "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.244345,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLCO",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "-0.020684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates",
            "url": "https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates",
            "time_published": "20240322T155900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.019198,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.143987",
                    "ticker_sentiment_score": "-0.056793",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLN",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.122052",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.327987",
                    "ticker_sentiment_score": "0.02653",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.143987",
                    "ticker_sentiment_score": "-0.107736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.413803",
                    "ticker_sentiment_score": "0.106632",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Gets Positive CHMP Opinion for Insulin Icodec",
            "url": "https://www.zacks.com/stock/news/2245039/novo-nordisk-nvo-gets-positive-chmp-opinion-for-insulin-icodec",
            "time_published": "20240322T155300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.947132"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.232698,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.254573",
                    "ticker_sentiment_score": "0.214349",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANIP",
                    "relevance_score": "0.254573",
                    "ticker_sentiment_score": "0.221684",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.204936",
                    "ticker_sentiment_score": "0.04705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "0.263112",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37892677/ozempic-users-speak-out-over-side-effects-lawsuits-against-novo-nordisk-and-eli-lilly-surge",
            "time_published": "20240322T143416",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.051356,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.354319",
                    "ticker_sentiment_score": "-0.213025",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.354319",
                    "ticker_sentiment_score": "-0.171064",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "0.126752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?",
            "url": "https://www.fool.com/investing/2024/03/22/with-shares-near-all-time-highs-is-it-a-buy/",
            "time_published": "20240322T143000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769867%2Fgettyimages-1434356176.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.31419,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.179788",
                    "ticker_sentiment_score": "0.159365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.069977",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.134156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.573651",
                    "ticker_sentiment_score": "0.473332",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.168048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.168048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Did Eli Lilly Just One-Up Novo Nordisk?",
            "url": "https://www.fool.com/investing/2024/03/22/did-eli-lilly-just-one-up-novo-nordisk/",
            "time_published": "20240322T111500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769751%2Fgettyimages-1434715649.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.400436,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.849481",
                    "ticker_sentiment_score": "0.572617",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "0.061272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.434763",
                    "ticker_sentiment_score": "0.164846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?",
            "url": "https://www.fool.com/investing/2024/03/22/this-under-radar-stock-just-hit-a-major-milestone/",
            "time_published": "20240322T101500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The mid-cap biotech has succeeded where many others failed.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769895/patient-talking-with-a-physician.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.097026,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.314711",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "0.074252",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "0.074252",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare Will Cover Weight Loss Drug Wegovy For Eligible Members",
            "url": "https://www.forbes.com/sites/antoniopequenoiv/2024/03/21/medicare-will-cover-weight-loss-drug-wegovy-for-eligible-members/",
            "time_published": "20240321T222546",
            "authors": [
                "Antonio Pequeño IV"
            ],
            "summary": "Medicare will soon cover popular weight loss drug Wegovy for its members, as long as they have heart disease and an increased risk of heart attack and other cardiovascular issues, the federal health insurance program confirmed with Forbes on Thursday, bucking the agency's trend of not providing ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fcb3af8f5e599d21b99041/0x0.jpg?format=jpg&crop=5200,3464,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.061443,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.095759",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare can pay for obesity drugs like Wegovy in certain heart patients",
            "url": "https://apnews.com/article/wegovy-medicare-part-d-heart-attack-stroke-288e551eb69914cb9803644290e01faf",
            "time_published": "20240321T204100",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "Medicare can pay for the popular weight-loss drug Wegovy - as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.",
            "banner_image": "https://dims.apnews.com/dims4/default/8eac1da/2147483647/strip/true/crop/5544x3693+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F26%2F26%2F37872ff7016e66bc1a7ff085bebb%2F6db70b11e50841f1908df3159b0f6c42",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.055865,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.07446",
                    "ticker_sentiment_score": "0.16879",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07446",
                    "ticker_sentiment_score": "-0.003094",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare Will Cover Weight-Loss Drugs - For Some People",
            "url": "https://www.investors.com/news/technology/weight-loss-drugs-wegovy-zepbound-eli-lilly-novo-nordisk/",
            "time_published": "20240321T190934",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Weight-Loss Drugs Win Medicare Coverage. Here's What It Means For Novo Nordisk, Eli Lilly Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/Stock-Medical-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.118183,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.554365",
                    "ticker_sentiment_score": "0.003392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.297061",
                    "ticker_sentiment_score": "-0.0594",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare can now cover certain weight loss drugs in a big step for patients",
            "url": "https://www.cnbc.com/2024/03/21/medicare-can-cover-weight-loss-drugs-if-used-for-added-health-benefit.html",
            "time_published": "20240321T184338",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Medicare patients can soon get coverage for Novo Nordisk's Wegovy as long as it is prescribed to reduce their risk of heart attacks and strokes.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107388182-17105168312024-03-08t160017z_281222543_rc2kh6adpeyy_rtrmadp_0_totw-obesity.jpeg?v=1710516917&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.036281,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "-0.075619",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37876911/wegovys-success-medicare-contemplates-covering-novo-nordisks-semaglutide-for-heart-health",
            "time_published": "20240321T172309",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In a significant development, Medicare may extend coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) to certain members with a history of heart disease.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142358,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167904",
                    "ticker_sentiment_score": "-0.061371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.403913",
                    "ticker_sentiment_score": "0.435666",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Awiqli®  ( once-weekly basal insulin icodec )  recommended for approval for the treatment of diabetes by the European regulatory authorities",
            "url": "https://www.globenewswire.com/news-release/2024/03/21/2850423/0/en/Awiqli-once-weekly-basal-insulin-icodec-recommended-for-approval-for-the-treatment-of-diabetes-by-the-European-regulatory-authorities.html",
            "time_published": "20240321T155500",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 21 March 2024 - Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending marketing authorisation for Awiqli® ( the brand name for once-weekly basal insulin icodec ) ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.141424,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.018389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.018389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.412298",
                    "ticker_sentiment_score": "0.128947",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Most Public Weight-Loss Journey in History",
            "url": "https://www.theatlantic.com/culture/archive/2024/03/oprah-winfrey-shame-blame-weight-loss-revolution-special/677827/",
            "time_published": "20240321T151801",
            "authors": [
                "Hannah Giorgis"
            ],
            "summary": "Nearly 13 years after the final episode of The Oprah Winfrey Show, it's easy to forget just how vicious the public scrutiny of Winfrey's body was during her talk show's decades-long run.",
            "banner_image": "https://cdn.theatlantic.com/thumbor/5ivBHAza5xbSbTpf0rgjWVKkvR0=/0x0:4800x2700/960x540/media/img/mt/2024/03/HR_171967_0163/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.085427,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029043",
                    "ticker_sentiment_score": "-0.02718",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Resolutions from the Annual General Meeting of Novo Nordisk A/S",
            "url": "https://www.globenewswire.com/news-release/2024/03/21/2850373/0/en/Resolutions-from-the-Annual-General-Meeting-of-Novo-Nordisk-A-S.html",
            "time_published": "20240321T145900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.120409,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.038075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.038075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.384608",
                    "ticker_sentiment_score": "0.19382",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "4 Fidelity Mutual Funds to Buy as Volatility Continues - C3.ai  ( NYSE:AI ) ",
            "url": "https://www.benzinga.com/news/24/03/37817519/4-fidelity-mutual-funds-to-buy-as-volatility-continues",
            "time_published": "20240321T145540",
            "authors": [
                "Zacks"
            ],
            "summary": "Fidelity Investments, one of the largest asset managers in the world, was founded in 1946 and is currently headquartered in Boston, MA. Proven efficiency in fund management and the ability to survive market volatility have enhanced the company's reputation over the years.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/20/markus-winkler-8t9qczz0-r8-unsplash.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999982"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.303595,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.092927",
                    "ticker_sentiment_score": "0.16111",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "THNOF",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.261564",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.092927",
                    "ticker_sentiment_score": "0.16111",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MUSA",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.107601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.114562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.126506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.114562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.107601",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy",
            "url": "https://www.fool.com/investing/2024/03/21/novo-nordisks-new-weight-loss-drug-could-be-better/",
            "time_published": "20240321T141500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Has Novo Nordisk's already red-hot stock become an even better buy?",
            "banner_image": "https://g.foolcdn.com/editorial/images/769571/a-group-of-scientists-looking-at-a-report.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.291662,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.461699",
                    "ticker_sentiment_score": "0.245209",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37859130/is-eli-lilly-winning-the-war-on-weight-loss-drugs-zepbound-overtakes-wegovy-in-us-prescriptions",
            "time_published": "20240320T210000",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Eli Lilly and Co. LLY enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound - the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.111981,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.194942",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16117",
                    "ticker_sentiment_score": "-0.1407",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.081001",
                    "ticker_sentiment_score": "0.07224",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tencent  ( TCEHY )  Q4 2023 Earnings Call Transcript",
            "url": "https://www.fool.com/earnings/call-transcripts/2024/03/20/tencent-tcehy-q4-2023-earnings-call-transcript/",
            "time_published": "20240320T194516",
            "authors": [
                "Motley Fool Transcribing"
            ],
            "summary": "TCEHY earnings call for the period ending December 31, 2023.",
            "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.281396,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.007639",
                    "ticker_sentiment_score": "0.087721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.003819",
                    "ticker_sentiment_score": "0.128848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.003819",
                    "ticker_sentiment_score": "0.044642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "III",
                    "relevance_score": "0.003819",
                    "ticker_sentiment_score": "0.148527",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BILI",
                    "relevance_score": "0.003819",
                    "ticker_sentiment_score": "0.053238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.003819",
                    "ticker_sentiment_score": "0.138444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TCTZF",
                    "relevance_score": "0.080074",
                    "ticker_sentiment_score": "0.162599",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MPNGY",
                    "relevance_score": "0.011458",
                    "ticker_sentiment_score": "0.10805",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?",
            "url": "https://www.investors.com/news/technology/pfizer-stock-buy-now/",
            "time_published": "20240320T170719",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/PFE-evergreen-051419-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                }
            ],
            "overall_sentiment_score": 0.120598,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.125315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.125315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.075008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.075008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.14606",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.687052",
                    "ticker_sentiment_score": "0.203831",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "0.059184",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.061869",
                    "ticker_sentiment_score": "-0.14606",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Celebrities who have used buzzy drugs like Ozempic for weight loss - and who's denied it",
            "url": "https://www.businessinsider.com/ozempic-celebrities-denied-semaglutide-wegovy-weight-loss-drugs-khloe-kardashian-2023-3",
            "time_published": "20240320T150000",
            "authors": [
                "Rachel Hosie",
                "Amber Middleton"
            ],
            "summary": "Stars Who Have Taken Weight Loss Drugs Like Ozempic, Wegovy - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.038495,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044885",
                    "ticker_sentiment_score": "-0.056517",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Stock Stalls On Oprah TV Special, But Reddit Traders Believe It's 'Not Done Yet' - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/03/37849114/novo-nordisk-stock-stalls-on-oprah-tv-special-but-reddit-traders-believe-its-not-done-yet",
            "time_published": "20240320T143643",
            "authors": [
                "Erica Kollmann"
            ],
            "summary": "Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk A/S NVO, weight-loss drug Ozempic and talk show host Oprah Winfrey.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/West-Bangal--India---April-20--2022--Nov_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.10348,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.714306",
                    "ticker_sentiment_score": "0.069245",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?",
            "url": "https://www.fool.com/investing/2024/03/20/novo-nordisk-versus-eli-lilly/",
            "time_published": "20240320T123000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The gap has been shrinking between these stocks over the past month.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769568/a-doctor-using-a-stethoscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.119613,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.412861",
                    "ticker_sentiment_score": "0.219186",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "0.216856",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss",
            "url": "https://www.investors.com/etfs-and-funds/etfs/weight-loss-drugs-feisty-rivals-take-on-eli-lilly-novo-nordisk/",
            "time_published": "20240320T120048",
            "authors": [
                "MATT KRANTZ",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995869"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.296034,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.365148",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.254973",
                    "ticker_sentiment_score": "0.274537",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.171325",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KROS",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.2681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "0.428918",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.242652",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MLYS",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.2681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics",
            "url": "https://www.zacks.com/stock/news/2243165/zacks-investment-ideas-feature-highlights-apple-alphabet-eli-lilly-novo-nordisk-and-viking-therapeutics",
            "time_published": "20240320T085400",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.031421,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.466811",
                    "ticker_sentiment_score": "0.006101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "0.074881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.672533",
                    "ticker_sentiment_score": "0.041285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.210579",
                    "ticker_sentiment_score": "0.06704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.466811",
                    "ticker_sentiment_score": "0.006101",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses - Less Eating, More Saving - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/03/37839883/tesla-investor-ross-gerber-backs-ozempics-potential-to-reduce-monthly-food-expenses-less-eating-more",
            "time_published": "20240320T082006",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X ( formerly Twitter ) to share his thoughts on the potential financial benefits of using Ozempic, a weight-loss drug developed by Novo Nordisk A/S NVO.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-Photo-by-Vidmir-Rais-via-Pix_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.09747,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.326283",
                    "ticker_sentiment_score": "0.181942",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.083833",
                    "ticker_sentiment_score": "0.396355",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Time to be \"Overweight\" Viking Therapeutics",
            "url": "https://www.zacks.com/commentary/2243036/time-to-be-overweight-viking-therapeutics",
            "time_published": "20240319T185800",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.008889",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.113166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.673107",
                    "ticker_sentiment_score": "0.048942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.148456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.123249",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.008889",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The maker of Ozempic is funding a new Nvidia-powered AI supercomputer | Business",
            "url": "https://www.cnn.com/2024/03/19/tech/novo-nordisk-ai-supercomputer/index.html",
            "time_published": "20240319T173300",
            "authors": [
                "Olesya Dmitracova"
            ],
            "summary": "The maker of Ozempic is funding a new Nvidia-powered AI supercomputer ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1258977076.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.311026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.491255",
                    "ticker_sentiment_score": "0.123154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "0.296146",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.207617",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.402941",
                    "ticker_sentiment_score": "0.387639",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic profits are helping fund a new Nvidia-powered AI supercomputer | Business",
            "url": "https://edition.cnn.com/2024/03/19/tech/novo-nordisk-ai-supercomputer/index.html",
            "time_published": "20240319T173300",
            "authors": [
                "Olesya Dmitracova"
            ],
            "summary": "Ozempic profits are helping fund a new Nvidia-powered AI supercomputer CNN International ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1258977076.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "edition.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.311026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.491255",
                    "ticker_sentiment_score": "0.123154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "0.296146",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.207617",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.402941",
                    "ticker_sentiment_score": "0.387639",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Healthy Returns: The first drug for a common, deadly liver disease is here - and more are coming",
            "url": "https://www.cnbc.com/2024/03/19/healthy-returns-first-nash-liver-disease-drug-is-here-more-coming.html",
            "time_published": "20240319T140805",
            "authors": [
                "Annika Kim Constantino",
                "Ashley Capoot"
            ],
            "summary": "Drugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI takes center stage at HIMSS.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/105649172-1545937328446gettyimages-911340738.jpeg?v=1710452648&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.064629,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "-0.058579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "-0.058579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.087017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.07627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.144795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGS",
                    "relevance_score": "0.031119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk on the Verge of Another Blockbuster Drug?",
            "url": "https://www.fool.com/investing/2024/03/19/is-novo-nordisk-on-verge-of-another-blockbuster/",
            "time_published": "20240319T140000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk just received some positive news for its latest obesity drug, amycretin.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769381%2Fgettyimages-1305194612.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.342556,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.10009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.021208",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.528475",
                    "ticker_sentiment_score": "0.502647",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Warning: This Skyrocketing Stock Has a Hidden Risk",
            "url": "https://www.fool.com/investing/2024/03/19/warning-this-skyrocketing-stock-has-a-hidden-risk/",
            "time_published": "20240319T134500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Don't bet on this pitfall happening, but know that it's a possibility.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769495/chart-reflected-on-investor-glasses.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.163581,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "-0.116059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.009023",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024",
            "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2024-302092898.html",
            "time_published": "20240319T123000",
            "authors": [
                "Flagship Pioneering"
            ],
            "summary": "Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...",
            "banner_image": "https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.493957,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.233025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MCRB",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FHTX",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.233025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNLI",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SANA",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.233025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.116631",
                    "ticker_sentiment_score": "0.134474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.233025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?",
            "url": "https://www.forbes.com/sites/greatspeculations/2024/03/19/should-you-pick-eli-lilly-stock-after-a-4x-rise-in-three-years/",
            "time_published": "20240319T120031",
            "authors": [
                "Trefis Team"
            ],
            "summary": "Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company's P/S ratio to ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f933b2ce306ad3e0975eb8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.317785,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.702129",
                    "ticker_sentiment_score": "0.562014",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.229058",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Did Novo Nordisk Just Get a Jump on Eli Lilly?",
            "url": "https://www.fool.com/investing/2024/03/19/did-novo-nordisk-just-say-checkmate-to-eli-lilly/",
            "time_published": "20240319T113000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "A recent FDA announcement may have just put one company in the lead.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769494%2Fmedicine-pills-fda-approval-stamp.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.260153,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.308504",
                    "ticker_sentiment_score": "0.189617",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.091571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47452",
                    "ticker_sentiment_score": "0.420823",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Hartford Multifactor Developed Markets  ( ex-US )  ETF  ( RODM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2242575/is-hartford-multifactor-developed-markets-ex-us-etf-rodm-a-strong-etf-right-now",
            "time_published": "20240319T102006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.186167,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.055008",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport' - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37815537/oprah-winfrey-tackles-weight-loss-drug-stigma-in-prime-time-special-amid-wegovy-ozempic-frenzy-fo",
            "time_published": "20240319T101613",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time special that delves into the stigma associated with weight loss drugs like Ozempic and Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.022123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.07423",
                    "ticker_sentiment_score": "0.012577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.220141",
                    "ticker_sentiment_score": "0.099838",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?",
            "url": "https://www.fool.com/investing/2024/03/19/madrigal-eli-lilly-novo-nordisk-better-stock-buy/",
            "time_published": "20240319T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Madrigal has one key advantage over its two huge potential future rivals.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769602/fda-blocks-in-hand.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.188805,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.113464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.558244",
                    "ticker_sentiment_score": "0.256798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.25377",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.484881",
                    "ticker_sentiment_score": "0.272744",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "4 Fidelity Mutual Funds to Buy as Volatility Continues",
            "url": "https://www.zacks.com/stock/news/2242584/4-fidelity-mutual-funds-to-buy-as-volatility-continues",
            "time_published": "20240319T093400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invest in Fidelity mutual funds like FPHAX, FDCAX, FMAGX and FDSCX for high returns alongside risk reduction in the current environment.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c1/45980.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999941"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.301378,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.159806",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "THNOF",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.250962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.159806",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MUSA",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.1072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.114144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.126061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.114144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.1072",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Novo Nordisk Foundation chooses Eviden to build \"Gefion\" in Denmark, one of the world's most powerful AI supercomputers",
            "url": "https://www.globenewswire.com/news-release/2024/03/19/2848310/0/en/The-Novo-Nordisk-Foundation-chooses-Eviden-to-build-Gefion-in-Denmark-one-of-the-world-s-most-powerful-AI-supercomputers.html",
            "time_published": "20240319T080000",
            "authors": [
                "Atos International"
            ],
            "summary": "Press Release ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c608800e-7f82-4fa8-8002-1244e8243814/image1.jpeg",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.374608,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AEXAF",
                    "relevance_score": "0.289381",
                    "ticker_sentiment_score": "0.344851",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.366661",
                    "ticker_sentiment_score": "0.233618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.289381",
                    "ticker_sentiment_score": "0.404426",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Rises Yet Lags Behind Market: Some Facts Worth Knowing",
            "url": "https://www.zacks.com/stock/news/2242474/novo-nordisk-nvo-rises-yet-lags-behind-market-some-facts-worth-knowing",
            "time_published": "20240318T215017",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.227934,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.299207",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37793319/inconsistent-insurance-coverage-for-weight-loss-drugs-novo-nordisks-glp-1s-face-hurdles-despite-h",
            "time_published": "20240318T165109",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The recent expansion of Novo Nordisk A/S's NVO Wegovy's ( semaglutide ) FDA approval has sparked a debate over insurance coverage for the drug. However, despite its potential health benefits, some employers and health plans remain hesitant to cover the drug due to its high monthly price of ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Insurance-stock-image_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.153467,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.247902",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37785607/us-prescriptions-race-for-weight-loss-drugs-eli-lillys-zepbound-overtakes-novo-nordisks-wegovy",
            "time_published": "20240318T142139",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY much-in-demand weight-loss drug Zepbound ( tirzepatide ) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S's NVO rival obesity medicine Wegovy ( semglutide ) for the first time since its launch.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/January-24--2024--Fort-Worth--Tx--Usa-A-.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.083401,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.062231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.468029",
                    "ticker_sentiment_score": "-0.003071",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.212439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "-0.027466",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847931/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240318T141800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 18 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.12545,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.200514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Options Trading: A Deep Dive into Market Sentiment - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37785325/novo-nordisk-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20240318T141602",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 76% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.164206,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.699089",
                    "ticker_sentiment_score": "0.19761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Earnings Growth & Price Strength Make Novo Nordisk  ( NVO )  a Stock to Watch",
            "url": "https://www.zacks.com/stock/news/2242075/earnings-growth-price-strength-make-novo-nordisk-nvo-a-stock-to-watch",
            "time_published": "20240318T133007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99489"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.330311,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.212842",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet",
            "url": "https://www.cnbc.com/2024/03/18/wegovy-heart-health-insurance-coverage.html",
            "time_published": "20240318T125501",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107364695-17062136162023-11-21t141915z_128434172_rc2oh4a2fo52_rtrmadp_0_health-obesity-novo-nordisk.jpeg?v=1710542227&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.036201,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.019411",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192234",
                    "ticker_sentiment_score": "0.116212",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: NVIDIA, Fastenal, HORIBA in Focus",
            "url": "https://www.zacks.com/stock/news/2242016/take-the-zacks-approach-to-beat-the-market-nvidia-fastenal-horiba-in-focus",
            "time_published": "20240318T120600",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                }
            ],
            "overall_sentiment_score": 0.198068,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.089231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "POWL",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.31294",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HRL",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.061304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.107832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UTI",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.238175",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.061304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSCO",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.101279",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.089231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ETN",
                    "relevance_score": "0.067823",
                    "ticker_sentiment_score": "0.124385",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLWYF",
                    "relevance_score": "0.033942",
                    "ticker_sentiment_score": "0.125889",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - BlackRock, Inc.",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847710/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
            "time_published": "20240318T113200",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.142267,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.646507",
                    "ticker_sentiment_score": "0.295339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - AIM International Mutual Funds",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847693/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
            "time_published": "20240318T112800",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.152916,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.499789",
                    "ticker_sentiment_score": "0.294618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Invesco Ltd.",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847688/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
            "time_published": "20240318T112500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.088322,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.155332",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How The World's Most Valuable Firms Are Upending The Concept Of Management",
            "url": "https://www.forbes.com/sites/stevedenning/2024/03/17/how-the-worlds-most-valuable-firms-are-upending-the-concept-of-management/",
            "time_published": "20240317T212023",
            "authors": [
                "Steve Denning"
            ],
            "summary": "The Drucker Forum, as part of its five-year effort to develop \"the next management,\" gave us a progress report last week. The theme of its conference in Vienna in November will be: \"managing for new levels of value creation and innovation\" with a particular focus on \"knowledge workers.\"",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f753ee0f13d01314a5bf81/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.385587,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.286219",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.030064",
                    "ticker_sentiment_score": "0.309422",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Isn't in The \"Magnificent Seven,\" but Here's Why I Think It Should Be",
            "url": "https://www.fool.com/investing/2024/03/17/novo-nordisk-isnt-in-the-magnificent-seven-but-her/",
            "time_published": "20240317T182800",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The drugmaker is magnificent in its own right.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769162/patient-talking-with-a-physician.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.337053,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.233333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.233333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.233333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "-0.115054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.233333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.655281",
                    "ticker_sentiment_score": "0.389958",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "-0.115054",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?",
            "url": "https://www.fool.com/investing/2024/03/17/novo-nordisk-is-already-working-on-wegovys-success/",
            "time_published": "20240317T134600",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The company continues to impress investors.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769051/doctor-with-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.369489,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.055109",
                    "ticker_sentiment_score": "0.112057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.466137",
                    "ticker_sentiment_score": "0.442438",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
            "url": "https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/",
            "time_published": "20240317T130000",
            "authors": [
                "Keith Speights",
                "and Prosper Junior Bakiny",
                "David Jagielski"
            ],
            "summary": "There's no need for delays in buying these great stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769331/young-woman-smiling-hands-behind-head.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.127458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.2256",
                    "ticker_sentiment_score": "-0.115588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "-0.165219",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.367141",
                    "ticker_sentiment_score": "0.252288",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?",
            "url": "https://www.fool.com/investing/2024/03/17/madrigal-pharmaceuticals-stock-screaming-buy/",
            "time_published": "20240317T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769446/scientists-smiling-and-shaking-hands.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.176811,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ETNB",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GALT",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVA",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.176287",
                    "ticker_sentiment_score": "0.171787",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TERN",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLMD",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGMT",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.007001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IQV",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year",
            "url": "https://www.businessinsider.com/recession-ozempic-wegovy-weight-loss-drugs-denmark-economy-novo-nordisk-2024-3",
            "time_published": "20240317T083100",
            "authors": [
                "George Glover"
            ],
            "summary": "Ozempic, Wegovy fattening up Denmark's economy, helped dodge recession - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.19373,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.134829",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?",
            "url": "https://www.fool.com/investing/2024/03/17/eli-lilly-taps-amazon-to-deliver-its-weight-manage/",
            "time_published": "20240317T072400",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769141%2Finvestor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.237044,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.51768",
                    "ticker_sentiment_score": "0.326446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.03811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.221313",
                    "ticker_sentiment_score": "0.322193",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.043944",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet",
            "url": "https://www.cnbc.com/2024/03/16/wegovy-heart-health-insurance-coverage.html",
            "time_published": "20240316T110001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107364695-17062136162023-11-21t141915z_128434172_rc2oh4a2fo52_rtrmadp_0_health-obesity-novo-nordisk.jpeg?v=1710542227&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.031381,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.019862",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.177294",
                    "ticker_sentiment_score": "0.111113",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Ginkgo Bioworks Stock a Buy?",
            "url": "https://www.fool.com/investing/2024/03/15/is-ginkgo-bioworks-stock-a-buy/",
            "time_published": "20240315T210700",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "There's a lot to like about this business, but it's still a risky bet.",
            "banner_image": "https://media.ycharts.com/charts/74621698c8c59b66f466e699446362cf.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.142906,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNA",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.189952",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.085958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.085958",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy and Zepbound Cast Shadow Over Madrigal's Liver Drug",
            "url": "https://www.barrons.com/amp/articles/madrigal-fda-approval-wegovy-zepbound-8efef084",
            "time_published": "20240315T203500",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "The Food and Drug Administration's approval of a liver drug from Madrigal Pharmaceuticals marks a turning point in the often-agonizing campaign to get a treatment onto the market for the condition known as MASH. It is also a reminder for investors that biopharma is opening other large markets ...",
            "banner_image": "https://images.barrons.com/im-83104388/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.058072,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.08756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.144526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.144526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37751575/heres-how-much-100-invested-in-novo-nordisk-10-years-ago-would-be-worth-today",
            "time_published": "20240315T153024",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.87% on an annualized basis producing an average annual return of 19.39%. Currently, Novo Nordisk has a market capitalization of $598.14 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.238974,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.9545",
                    "ticker_sentiment_score": "0.384186",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Nasdaq, S&P 500 Extend Losses; Adobe Sell-Off Casts Pall On Tech; Ulta Beauty Tumbles",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-adobe-stock/",
            "time_published": "20240315T144448",
            "authors": [
                "KEN SHREVE",
                "Investor's Business Daily"
            ],
            "summary": "Nasdaq, S&P 500 Extend Losses. Adobe Sell-Off Casts Pall On Tech. Ulta Beauty Tumbles Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999921"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.073182,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.128398",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.001903",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.080304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADBE",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.011581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.242862",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CLSK",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.077214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.103425",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic",
            "url": "https://www.fool.com/investing/2024/03/15/novo-nordisk-just-scored-a-huge-win-and-its-not/",
            "time_published": "20240315T141500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769052%2Fdoctor-holding-heart-organ-transplant-concept.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.248654,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.769861",
                    "ticker_sentiment_score": "0.46919",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  is a Top Momentum Stock for the Long-Term",
            "url": "https://www.zacks.com/stock/news/2241407/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term",
            "time_published": "20240315T135011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default102.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": 0.379033,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.410505",
                    "ticker_sentiment_score": "0.264705",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Stocks That Have More Than Tripled This Year: Are They Buys?",
            "url": "https://www.fool.com/investing/2024/03/15/2-stocks-that-have-more-than-tripled-this-year-are/",
            "time_published": "20240315T134500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Don't jump on the bandwaggon too quickly.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768669/doctor-holding-elderly-patients-hand.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.125568,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "0.252912",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.048621",
                    "ticker_sentiment_score": "0.081999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JANX",
                    "relevance_score": "0.330496",
                    "ticker_sentiment_score": "0.186751",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More",
            "url": "https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azns-new-acquisition-fda-updates-for-nvo-lly-and-more",
            "time_published": "20240315T131900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.200599,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.06412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169378",
                    "ticker_sentiment_score": "0.118514",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.105455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.210823",
                    "ticker_sentiment_score": "0.128918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.083978",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why weight-loss drugs like Ozempic are a game-changer for the global economy",
            "url": "https://www.businessinsider.com/economic-outlook-ozempic-economy-obesity-gdp-productivity-healthcare-novo-nordisk-2024-3",
            "time_published": "20240315T120800",
            "authors": [
                "Phil Rosen"
            ],
            "summary": "Weight-loss drugs like Ozempic are game-changers for economic outlook - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.228489,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.050983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.110779",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Move Over, Tesla! These 6 Stocks Could Replace It in the \"Magnificent 7\"",
            "url": "https://www.fool.com/investing/2024/03/15/move-over-tesla-these-6-stocks-could-replace-it-in/",
            "time_published": "20240315T114600",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Tesla is failing to keep pace with the rest of the Magnificent Seven.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769058/brk-4.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.308524,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.202585",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.202585",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.246414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.095498",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.181921",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.092116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.255106",
                    "ticker_sentiment_score": "0.030308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.3038",
                    "ticker_sentiment_score": "0.258595",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.3038",
                    "ticker_sentiment_score": "0.237763",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Russell Investments Mutual Funds for Solid Returns",
            "url": "https://www.zacks.com/stock/news/2241180/3-russell-investments-mutual-funds-for-solid-returns",
            "time_published": "20240315T111900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Consider investing in Russell Investments mutual funds like RTITX, RGECX and RTDSX for a diversified portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/344.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.226015,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.147366",
                    "ticker_sentiment_score": "0.030437",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.048346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.049354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.049354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYDAF",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.049354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.048346",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Does Tesla Still Belong in the \"Magnificent Seven?\"",
            "url": "https://www.fool.com/investing/2024/03/15/does-tesla-still-belong-in-the-magnificent-seven/",
            "time_published": "20240315T100600",
            "authors": [
                "Billy Duberstein"
            ],
            "summary": "There's a case to be made that Tesla no longer qualifies as a \"must-own\" stock along with its six other big tech peers.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769254%2Ftesla-cybertruck-on-road.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.209824,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.089009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.089009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.089009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.089009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.029113",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.618922",
                    "ticker_sentiment_score": "0.168552",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029113",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.029113",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.116067",
                    "ticker_sentiment_score": "0.080788",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.029113",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?",
            "url": "https://www.fool.com/investing/2024/03/15/pfizer-viking-therapeutics-eli-lilly-novo-nordisk/",
            "time_published": "20240315T095000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Viking Therapeutics just might be an attractive acquisition target for Pfizer.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769056/big-fish-eating-little-fish.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.143119,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "0.149347",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.16697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.212839",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "0.149347",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.823212",
                    "ticker_sentiment_score": "0.234987",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease",
            "url": "https://www.cnbc.com/2024/03/14/fda-approves-nash-liver-disease-drug-from-madrigal-pharmaceuticals.html",
            "time_published": "20240314T222010",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed - or are still trying to break into.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107387832-1710452490047-gettyimages-1984519715-RAFAPRESS_06022024-00038.jpeg?v=1710452538&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.059231,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.060856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.14472",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Smart Money Is Betting Big In NVO Options - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37707401/smart-money-is-betting-big-in-nvo-options",
            "time_published": "20240314T151741",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.083566,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.669956",
                    "ticker_sentiment_score": "0.25415",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Partners Amazon to Deliver Drugs Like Zepbound",
            "url": "https://www.zacks.com/stock/news/2240711/lilly-lly-partners-amazon-to-deliver-drugs-like-zepbound",
            "time_published": "20240314T135400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.235264,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.709611",
                    "ticker_sentiment_score": "0.264861",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.402941",
                    "ticker_sentiment_score": "0.151039",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "0.296485",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.",
            "url": "https://www.fool.com/investing/2024/03/14/missed-novo-nordisk-this-smaller-danish-biotech/",
            "time_published": "20240314T091500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The risk is higher, but so is the upside when it comes to Zealand Pharma.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768796/a-team-of-scientists-reviewing-results-in-a-lab.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.236313,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.333246",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.202437",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.202437",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Experts hesitate on weight loss ETFs amid the obesity drug boom",
            "url": "https://www.cnbc.com/2024/03/13/weight-loss-etfs-may-sit-out-obesity-drug-mania-experts-say.html",
            "time_published": "20240313T230001",
            "authors": [
                "Anna Gleason"
            ],
            "summary": "While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107385852-1710189287ETF-SEG2-031124.jpg?v=1710189286&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.108075,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.185424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.185424",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Tesla's Stock Dip Drops Elon Musk Behind Bezos To World's Third-Richest Person",
            "url": "https://www.forbes.com/sites/dereksaul/2024/03/13/teslas-stock-dip-drops-elon-musk-behind-bezos-to-worlds-third-richest-person/",
            "time_published": "20240313T192320",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Tesla shares tanked to a fresh 10-month low Wednesday as Wall Street turns increasingly bearish on the American electric vehicle maker, sending the net worth of Tesla's polarizing centibillionaire CEO Elon Musk plunging.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f1fd04c456a06ca398e0ad/0x0.jpg?format=jpg&crop=1379,776,x0,y232,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.16766,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.099511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.105202",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.878471",
                    "ticker_sentiment_score": "0.286354",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.075179",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.105202",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.075179",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amazon Pharmacy will deliver Eli Lilly's Zepbound, other drugs to customers' doorsteps",
            "url": "https://www.foxbusiness.com/lifestyle/amazon-pharmacy-will-deliver-eli-lillys-zepbound-other-drugs-customers-doorsteps",
            "time_published": "20240313T180600",
            "authors": [],
            "summary": "Amazon will now deliver pharmaceutical giant Eli Lilly's diabetes and weight-loss medications to customers' doors. Amazon Pharmacy announced Wednesday that it will serve as a third-party dispensing provider for LillyDirect, the pharmaceutical company's new telehealth site.",
            "banner_image": "https://static.foxbusiness.com/foxbusiness.com/content/uploads/2024/03/Zepbound-injection-Eli-Lilly.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.244207,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.042705",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Teams Up With Amazon To Deliver Weight-Loss Drug",
            "url": "https://www.investors.com/news/technology/eli-lilly-amazon-pharmacy-lillydirect-weight-loss-drug-zepbound/",
            "time_published": "20240313T171932",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.035732,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "-0.041654",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "-0.070742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "-0.242397",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.364987",
                    "ticker_sentiment_score": "0.088979",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150592",
                    "ticker_sentiment_score": "-0.127667",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs - Agilent Technologies  ( NYSE:A ) , Avantor  ( NYSE:AVTR ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37668318/top-7-biotech-winners-of-novo-nordisk-eli-lillys-outsourcing-strategy-for-weight-lo",
            "time_published": "20240313T163538",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Genetic-Research-And-Biotech-Science-Con_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.276455,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "A",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.114066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.139069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.072735",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APG",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.107571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.03309",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.387674",
                    "ticker_sentiment_score": "0.279985",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.189468",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DHR",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.34917",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/dexcom-stock-buy-zone-diabetes-obesity-continuous-glucose-monitors/",
            "time_published": "20240313T160442",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-13-24DXCM.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                }
            ],
            "overall_sentiment_score": 0.138038,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.053149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.10132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.10132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "-0.23901",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.152339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.053149",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37662893/pharmaceutical-crime-jumps-50-as-criminals-seek-to-capitalize-rising-tide-of-counterfeit-weight-l",
            "time_published": "20240313T143118",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has intensified.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.134047,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "-0.088767",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.358152",
                    "ticker_sentiment_score": "0.130736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Tesla, Airbnb, ONEOK and CDW",
            "url": "https://www.zacks.com/stock/news/2240060/the-zacks-analyst-blog-highlights-novo-nordisk-tesla-airbnb-oneok-and-cdw",
            "time_published": "20240313T134800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk, Tesla, Airbnb, ONEOK and CDW are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b9/441.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.283764,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "OKE",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.036961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.138637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.107751",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.219305",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CDW",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.036961",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 No-Brainer Stocks I'd Add to the \"Magnificent Seven\"",
            "url": "https://www.fool.com/investing/2024/03/13/2-no-brainer-stocks-id-add-to-magnificent-seven/",
            "time_published": "20240313T134500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "They fit right in.",
            "banner_image": "https://media.ycharts.com/charts/e88a70f1dbaeb58217edf59cea01b1d9.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.394698,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.22383",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.508232",
                    "ticker_sentiment_score": "0.4881",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.096535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.167998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.228793",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.167998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.126736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338251",
                    "ticker_sentiment_score": "0.465553",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs",
            "url": "https://www.forbes.com/sites/roberthart/2024/03/13/ozempic-and-wegovy-rivals-here-are-the-companies-working-on-competitor-weight-loss-drugs/",
            "time_published": "20240313T112008",
            "authors": [
                "Robert Hart"
            ],
            "summary": "The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market - here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65df4c6fa9185c9f89605cd4/0x0.jpg?format=jpg&crop=3167,1780,x0,y89,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.131524,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.058547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.011491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "0.078489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.058547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.058547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TERN",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.058547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "0.058547",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?",
            "url": "https://www.fool.com/investing/2024/03/13/could-viking-therapeutics-challenge-eli-lilly/",
            "time_published": "20240313T090300",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking aims to enter a market that may be worth $100 billion in a few years.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769012%2Fgettyimages-doctors-talking.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.185992,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.50287",
                    "ticker_sentiment_score": "0.280042",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.316184",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.131463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "-0.046408",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Appointment of new CEO",
            "url": "https://www.globenewswire.com/news-release/2024/03/13/2845202/0/en/Appointment-of-new-CEO.html",
            "time_published": "20240313T083000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. 255 ( Changed category - Inside information ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.170644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Appointment of new CEO",
            "url": "https://www.globenewswire.com/news-release/2024/03/13/2845193/0/en/Appointment-of-new-CEO.html",
            "time_published": "20240313T080200",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.170644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Was a Winner Today",
            "url": "https://www.fool.com/investing/2024/03/12/why-novo-nordisk-stock-was-a-winner-today/",
            "time_published": "20240313T003105",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A team of analysts believes the popular company has excellent potential for future growth.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769107/patient-and-physician-smiling-during-a-visit.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.328568,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COF",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.538389",
                    "ticker_sentiment_score": "0.466312",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Ozempic Revolution Is Stuck",
            "url": "https://www.theatlantic.com/health/archive/2024/03/ozempic-revolution-stuck/677736/",
            "time_published": "20240312T221700",
            "authors": [
                "Yasmin Tayag"
            ],
            "summary": "The irony undergirding the new wave of obesity drugs is that they initially weren't created for obesity at all. The profound weight loss spurred by Ozempic, a diabetes drug in the class of so-called GLP-1 agonists, gave way to Wegovy-the same drug, repackaged for obesity.",
            "banner_image": "https://cdn.theatlantic.com/thumbor/Y8ow09ciDJPAipo5uFKXmfRgHpg=/0x0:2000x1125/960x540/media/img/mt/2024/03/ozempic_access/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.017172,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "0.043994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.243864",
                    "ticker_sentiment_score": "0.031037",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Research Reports for Novo Nordisk, Tesla & Airbnb",
            "url": "https://www.zacks.com/research-daily/2239296/top-research-reports-for-novo-nordisk-tesla-airbnb",
            "time_published": "20240312T215800",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Tesla, Inc. (TSLA) and Airbnb, Inc. (ABNB).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.344211,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184598",
                    "ticker_sentiment_score": "0.247713",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.092927",
                    "ticker_sentiment_score": "0.150045",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.092927",
                    "ticker_sentiment_score": "0.150333",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The dominance of the US economy and the stock market in 4 charts",
            "url": "https://markets.businessinsider.com/news/stocks/stock-market-outlook-us-economic-dominance-gdp-charts-goldman-sachs-2024-3",
            "time_published": "20240312T165500",
            "authors": [
                "Phil Rosen"
            ],
            "summary": "Stock Market Outlook: US Economic, Market Dominance in 4 Charts - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.239794,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.340134",
                    "ticker_sentiment_score": "0.243831",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.079022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.013017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.079022",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "All You Need to Know About Novo Nordisk  ( NVO )  Rating Upgrade to Buy",
            "url": "https://www.zacks.com/stock/news/2239424/all-you-need-to-know-about-novo-nordisk-nvo-rating-upgrade-to-buy",
            "time_published": "20240312T160009",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997845"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                }
            ],
            "overall_sentiment_score": 0.318187,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.364275",
                    "ticker_sentiment_score": "0.348316",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What Makes Novo Nordisk  ( NVO )  a Strong Momentum Stock: Buy Now?",
            "url": "https://www.zacks.com/stock/news/2239429/what-makes-novo-nordisk-nvo-a-strong-momentum-stock-buy-now",
            "time_published": "20240312T160008",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.297835,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.604596",
                    "ticker_sentiment_score": "0.397538",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "What's Going On With Fractyl Health Stock Tuesday? - Fractyl Health  ( NASDAQ:GUTS ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37623234/newly-listed-obesity-player-fractyl-health-shares-encouraging-preclinical-data",
            "time_published": "20240312T145310",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Fractyl Health Inc GUTS released new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy platform.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/pharma-lab-worker-ai_7.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.018991,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GUTS",
                    "relevance_score": "0.565345",
                    "ticker_sentiment_score": "0.006769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.164225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TRGNF",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.027815",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Is Considered a Good Investment by Brokers: Is That True?",
            "url": "https://www.zacks.com/stock/news/2239193/novo-nordisk-nvo-is-considered-a-good-investment-by-brokers-is-that-true",
            "time_published": "20240312T133011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default108.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.329961,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.230788",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss",
            "url": "https://www.globenewswire.com/news-release/2024/03/12/2844447/11676/en/Veru-Announces-the-Appointment-of-Louis-Aronne-MD-as-Chief-Medical-Advisor-for-its-Enobosarm-Program-for-High-Quality-Weight-Loss.html",
            "time_published": "20240312T120000",
            "authors": [
                "Veru Inc."
            ],
            "summary": "MIAMI, March 12, 2024 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ: VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome ( ARDS ) , today ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/9c96f1a7-e104-47d4-8011-8c19496681c2",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.007304,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.0203",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERU",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.022775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.0203",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.0203",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.0203",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant",
            "url": "https://www.fool.com/investing/2024/03/12/1-big-new-reason-to-buy-novo-nordisk-stock-hand-ov/",
            "time_published": "20240312T114500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The pharma giant could have yet another knockout obesity drug on the way.",
            "banner_image": "https://media.ycharts.com/charts/5c068ae6a3c61bfe2d5aa4e4398ea40e.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.18728,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.089984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.089984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.323785",
                    "ticker_sentiment_score": "0.129602",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY",
            "url": "https://www.globenewswire.com/news-release/2024/03/12/2844424/0/en/ARECOR-AND-TRx-BIOSCIENCES-ESTABLISH-RESEARCH-COLLABORATION-TO-DEVELOP-ORAL-GLP-1-WITH-ENHANCED-BIOAVAILABILITY.html",
            "time_published": "20240312T113000",
            "authors": [
                "Arecor Therapeutics plc"
            ],
            "summary": "Arecor Therapeutics plc ( \"Arecor\" or the \"Company\" ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/90dff5e5-3d86-4f0e-bff2-b8114123328c",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.366931,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.02004",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity - Syra Health  ( NASDAQ:SYRA ) , Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/03/37609930/us-health-agency-reviews-novo-nordisks-wegovy-for-potential-use-in-treating-heart-disease-patients-w",
            "time_published": "20240312T085307",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "The Centers for Medicare and Medicaid Services ( CMS ) is considering the inclusion of Novo Nordisk's NVO obesity drug Wegovy in its coverage for heart disease patients with obesity.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-and-other-drugs-for-weight-loss_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.062213,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "-0.035353",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Indivior Sees Composite Rating Climb To 97",
            "url": "https://www.investors.com/ibd-data-stories/indivior-sees-composite-rating-climb-to-97/",
            "time_published": "20240312T080000",
            "authors": [
                "Investor's Business Daily",
                "INVESTOR'S BUSINESS DAILY"
            ],
            "summary": "On Tuesday, Indivior ( INDV ) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 97. X The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Indivior is currently forming a cup with handle, with a ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.275102,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "INDV",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "-0.147051",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic - 'Shame, Blame And The Weight Loss Revolution' - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/03/37605412/gary-black-keeping-tabs-on-oprahs-upcoming-tv-special-about-ozempic-shame-blame-and-the-weight-loss",
            "time_published": "20240312T050946",
            "authors": [
                "Ananya Gairola"
            ],
            "summary": "Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey's upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.08539,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.396574",
                    "ticker_sentiment_score": "-0.088506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.068821",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT",
            "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-catalent-inc---ctlt-302085976.html",
            "time_published": "20240312T002200",
            "authors": [
                "Pomerantz LLP"
            ],
            "summary": "NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( \"Catalent\" or the \"Company\" ) ( NYSE: CTLT ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.",
            "banner_image": "https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.098562,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.632565",
                    "ticker_sentiment_score": "0.176659",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.3007",
                    "ticker_sentiment_score": "0.137296",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  Dipped More Than Broader Market Today",
            "url": "https://www.zacks.com/stock/news/2238901/why-novo-nordisk-nvo-dipped-more-than-broader-market-today",
            "time_published": "20240311T215018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default136.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.270204,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.672055",
                    "ticker_sentiment_score": "0.421229",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Anti-Counterfeiting Group Identifies Fake Diabetes Drug Ozempic in 16 Countries: Sparks Patient Harm Concerns - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37595038/anti-counterfeiting-group-identifies-fake-diabetes-drug-ozempic-in-16-countries-sparks-patient-ha",
            "time_published": "20240311T173126",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic ( semaglutide ) , Novo Nordisk A/S's NVO CEO, Lars Fruergaard Jorgensen, reportedly affirmed the company is collaborating with authorities across multiple countries.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-maker-Novo-Nordisk_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.138476,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28008",
                    "ticker_sentiment_score": "0.208574",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' - AstraZeneca  ( NASDAQ:AZN ) , ASML Holding  ( NASDAQ:ASML ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37589143/top-wall-street-analysts-flag-us-market-concentration-anxiety-advise-investors-to-a",
            "time_published": "20240311T143834",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Goldman Sachs has flagged an increasing concern over the U.S. stock market's heavy concentration and the dominant sway of its largest tech stocks, urging investors to broaden their geographical diversification.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/stock-market-barbell.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.130845,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SAP",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.427425",
                    "ticker_sentiment_score": "0.014605",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.074926",
                    "ticker_sentiment_score": "-0.052434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.074926",
                    "ticker_sentiment_score": "-0.010117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.074926",
                    "ticker_sentiment_score": "-0.010117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.149192",
                    "ticker_sentiment_score": "-0.01278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.074926",
                    "ticker_sentiment_score": "-0.010117",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lumen Technologies' CEO On Their People-First Reset",
            "url": "https://www.forbes.com/sites/meganpoinski/2024/03/11/lumen-technologies-ceo-on-their-people-first-reset/",
            "time_published": "20240311T135646",
            "authors": [
                "Megan Poinski"
            ],
            "summary": "This is the published version of Forbes' CEO newsletter, which offers the latest news for today's and tomorrow's business leaders and decision makers. Click here to get it delivered to your inbox every Sunday. Admitting that you were wrong is difficult, but it's something leaders do.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ef0ccf42e9cdee66b49a41/0x0.jpg?format=jpg&crop=7083,3987,x0,y650,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.11714,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMAT",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "0.064276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "0.064276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "0.064276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "0.064276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "-0.000872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LUMN",
                    "relevance_score": "0.05093",
                    "ticker_sentiment_score": "0.089596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XEL",
                    "relevance_score": "0.05093",
                    "ticker_sentiment_score": "-0.061009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.168608",
                    "ticker_sentiment_score": "-0.040326",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.067871",
                    "ticker_sentiment_score": "0.123765",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Novo Nordisk  ( NVO )  is a Strong Growth Stock",
            "url": "https://www.zacks.com/stock/news/2238638/heres-why-novo-nordisk-nvo-is-a-strong-growth-stock",
            "time_published": "20240311T134511",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default287.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.435657,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.482078",
                    "ticker_sentiment_score": "0.441098",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/03/11/2843796/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240311T124600",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 11 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.12545,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.200514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus",
            "url": "https://www.zacks.com/stock/news/2238514/beat-the-market-like-zacks-walmart-novo-nordisk-procter-gamble-in-focus",
            "time_published": "20240311T120300",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/26/123.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.179916,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SLDB",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.107441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SE",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.060362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.106435",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.060362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.060393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACMR",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.246641",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CL",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.060393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFM",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.124548",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VXRT",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.246641",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OCUL",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.253722",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.104078",
                    "ticker_sentiment_score": "0.114023",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's  ( NVO )  Wegovy Gets FDA Nod to Reduce Heart Risk",
            "url": "https://www.zacks.com/stock/news/2238445/novo-nordisks-nvo-wegovy-gets-fda-nod-to-reduce-heart-risk",
            "time_published": "20240311T105900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.07767,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "0.229078",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FGEN",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "-0.028692",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.433215",
                    "ticker_sentiment_score": "-0.103756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACET",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "-0.028666",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Viking Therapeutics Stock a Buy?",
            "url": "https://www.fool.com/investing/2024/03/11/is-viking-therapeutics-stock-a-buy/",
            "time_published": "20240311T105300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Its potential is looking increasingly more likely to be realized.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768656/investors-drinks-and-examines-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.198363,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.226477",
                    "ticker_sentiment_score": "0.250148",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114409",
                    "ticker_sentiment_score": "0.155224",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Fidelity Mutual Funds to Buy Now for Long-Term Growth",
            "url": "https://www.zacks.com/stock/news/2238420/3-fidelity-mutual-funds-to-buy-now-for-long-term-growth",
            "time_published": "20240311T103900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invest in Fidelity mutual funds like FPHAX, FMAGX and FADTX for their reliability and potential for growth.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.252524,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.123209",
                    "ticker_sentiment_score": "0.058221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.123209",
                    "ticker_sentiment_score": "0.058221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.051002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.043001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.043001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.051002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF  ( DNL )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2238414/is-wisdomtree-global-ex-us-quality-dividend-growth-etf-dnl-a-strong-etf-right-now",
            "time_published": "20240311T102005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.308896,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.065989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.186182",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WT",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.302164",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.065989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.065989",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - BlackRock, Inc.",
            "url": "https://www.globenewswire.com/news-release/2024/03/11/2843540/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
            "time_published": "20240311T093000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.164459,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.344368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Forget Tesla: I Think This Stock Should Replace It in the \"Magnificent Seven\"",
            "url": "https://www.fool.com/investing/2024/03/10/forget-tesla-i-think-this-stock-should-replace-it/",
            "time_published": "20240310T132900",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Tesla doesn't look very magnificent these days. But there's another stock that does.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768602/scientist-smiling-holding-tablet-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.17247,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.110973",
                    "ticker_sentiment_score": "0.191625",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.469935",
                    "ticker_sentiment_score": "0.031351",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.514619",
                    "ticker_sentiment_score": "0.12536",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?",
            "url": "https://www.fool.com/investing/2024/03/10/is-novo-nordisk-a-buy-after-its-new-obesity-candid/",
            "time_published": "20240310T083300",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Encouraging results recently pushed the pharma stock up to new heights.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768402%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.217219,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.113866",
                    "ticker_sentiment_score": "0.112083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.057079",
                    "ticker_sentiment_score": "0.130125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.526003",
                    "ticker_sentiment_score": "0.344971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The obese numbers",
            "url": "https://www.financialexpress.com/lifestyle/health/the-obese-numbers/3420142/",
            "time_published": "20240309T223000",
            "authors": [
                "Ivinder Gill"
            ],
            "summary": "Obesity is rising at alarming levels. So is its economic impact. Unsurprisingly, the business of weight loss is also getting fatter by the day. It has been dubbed the story of the decade. And, we really didn't need the new Lancet report on rising obesity to tell us that.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/03/Obesity-Freepik.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.009632,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.023838",
                    "ticker_sentiment_score": "0.068689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.023838",
                    "ticker_sentiment_score": "0.113495",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.",
            "url": "https://www.fool.com/investing/2024/03/09/missed-out-on-eli-lilly-novo-nordisk-this-could/",
            "time_published": "20240309T214700",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767725/team-of-traders-working-in-an-office.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.166914,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.067061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.100716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.172421",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges",
            "url": "https://www.forbes.com/sites/joshuacohen/2024/03/09/legal-challenges-to-ira-drug-price-negotiations-face-skeptical-judges/",
            "time_published": "20240309T174448",
            "authors": [
                "Joshua Cohen"
            ],
            "summary": "A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65eb1178e7f08fb8331f00d8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.009656,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FGROF",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "0.013937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169477",
                    "ticker_sentiment_score": "0.018762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056876",
                    "ticker_sentiment_score": "-0.035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "-0.016752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "-0.016752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug",
            "url": "https://www.foxbusiness.com/fox-news-health/wegovy-weight-loss-medication-fda-approval-heart-disease-prevention-drug",
            "time_published": "20240309T130500",
            "authors": [
                "Melissa Rudy"
            ],
            "summary": "Wegovy has been approved for use as a heart disease prevention medication, the FDA announced on Friday.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/8a599a9a-53dd-43a2-8ff7-b1e5162b025a/e280edcf-0404-42c0-bdc3-9043c3f1786f/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.073065,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FOX",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.179502",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.199544",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.",
            "url": "https://www.fool.com/investing/2024/03/09/missed-out-on-eli-lilly-3-healthcare-stocks-with-b/",
            "time_published": "20240309T105200",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Good news could be in store for all three of these drugmakers.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768349/scientists-looking-at-screen-with-icons.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.203035,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.088635",
                    "ticker_sentiment_score": "-0.023012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.088635",
                    "ticker_sentiment_score": "0.216933",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.088635",
                    "ticker_sentiment_score": "-0.025548",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044386",
                    "ticker_sentiment_score": "0.037547",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Eli Lilly the Best Pharmaceutical Stock for You?",
            "url": "https://www.fool.com/investing/2024/03/09/is-eli-lilly-the-best-pharmaceutical-stock-for-you/",
            "time_published": "20240309T100700",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Lilly's recently approved weight-loss drug is off to a good start.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768573%2Fgettyimages-1276837766.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999986"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.271218,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.055364",
                    "ticker_sentiment_score": "0.037895",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.555067",
                    "ticker_sentiment_score": "0.35693",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055364",
                    "ticker_sentiment_score": "0.034028",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates",
            "url": "https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvos-new-obesity-pill-data-rhhby-azns-pipeline-updates",
            "time_published": "20240309T061400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.081666,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.293506",
                    "ticker_sentiment_score": "0.035406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.050044",
                    "ticker_sentiment_score": "-0.119234",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Approves Expanded Indication For Novo Nordisk's Wegovy To Reduce Cardiovascular Risk",
            "url": "https://markets.businessinsider.com/news/stocks/fda-approves-expanded-indication-for-novo-nordisk-s-wegovy-to-reduce-cardiovascular-risk-1033147830",
            "time_published": "20240309T042501",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "( RTTNews ) - Novo Nordisk ( NVO ) said that the U.S. Food and Drug Administration has approved an additional indication for Wegovy to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight ...",
            "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.002486,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.066174",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies - Or Could They Get Another Lift? - Eli Lilly and Co  ( NYSE:LLY ) , Walt Disney  ( NYSE:DIS ) ",
            "url": "https://www.benzinga.com/general/entertainment/24/03/37570233/oprah-winfrey-to-spotlight-weight-loss-drugs-in-new-tv-special-will-shame-blame-come-to-dru",
            "time_published": "20240308T215905",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Legendary television mogul Oprah Winfrey recently announced she was stepping down from the board of directors of WeightWatchers. The announcement, along with fourth-quarter financial results, sent shares of WeightWatchers parent WW International WW lower last month.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Oprah-Winfrey_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.118269,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.136821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.127329",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update",
            "url": "https://www.cnn.com/2024/03/08/health/wegovy-heart-benefits/index.html",
            "time_published": "20240308T203600",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "Wegovy's not just for weight loss anymore. The US Food and Drug Administration on Friday approved drugmaker Novo Nordisk's application to add cardiovascular benefits to the medicine's label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke or ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240130161837-ozempic-wegovy-questions-answered-gupta.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004917,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "-0.153053",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients",
            "url": "https://apnews.com/article/wegovy-semaglutide-heart-attack-stroke-fda-label-ccbc1fc44ee43f8536596d5f7bbd6876",
            "time_published": "20240308T195800",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, . The U.S.",
            "banner_image": "https://dims.apnews.com/dims4/default/c4aff7a/2147483647/strip/true/crop/3355x2235+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F19%2F06%2F348ab4a05a695a7f3e6cc5426d0e%2F243b90fed5ca46ffa7dae481069193f4",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.102946,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.167001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.130157",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity",
            "url": "https://www.prnewswire.com/news-releases/wegovy-receives-fda-approval-for-cardiovascular-risk-reduction-in-adults-with-known-heart-disease-and-overweight-or-obesity-302084454.html",
            "time_published": "20240308T195700",
            "authors": [
                "Novo Nordisk"
            ],
            "summary": "Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight ... PR ...",
            "banner_image": "http://mma.prnewswire.com/media/466582/Novo_Nordisk_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.088059,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.016205",
                    "ticker_sentiment_score": "0.107401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080892",
                    "ticker_sentiment_score": "0.09818",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i",
            "time_published": "20240308T193628",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Novo Nordisk A/S NVO's Wegovy garnered the Food and Drug Administration's approval for expanded use Friday, marking what the drugmaker said is a pivotal turn in the treatment landscape for individuals grappling with the dual challenges of obesity and established cardiovascular disease.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.108848,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.098736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo's Weight-Loss Blockbuster Wins Another Approval",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cardiovascular-fda/",
            "time_published": "20240308T193100",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-NovoNordisk-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                }
            ],
            "overall_sentiment_score": -0.032259,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.625937",
                    "ticker_sentiment_score": "0.109844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "-0.073296",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.625937",
                    "ticker_sentiment_score": "-0.329709",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage",
            "url": "https://www.cnbc.com/2024/03/08/novo-nordisks-wegovy-wins-fda-approval-for-heart-health-benefits-in-move-that-could-expand-insurance-coverage.html",
            "time_published": "20240308T190238",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107364694-17062136162023-11-21t141914z_82196440_rc2oh4ah9cpp_rtrmadp_0_health-obesity-novo-nordisk.jpeg?v=1707513174&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.109395,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "-0.047911",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease",
            "url": "https://www.globenewswire.com/news-release/2024/03/08/2843283/0/en/Wegovy-approved-in-the-US-for-cardiovascular-risk-reduction-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease.html",
            "time_published": "20240308T184200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 8 March 2024 - Novo Nordisk today announced that the US Food and Drug Administration ( FDA ) has approved a label expansion for Wegovy® based on a supplemental New Drug Application ( sNDA ) for the indication of reducing risks of major adverse cardiovascular events ( MACE ) ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": -0.055935,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.044634",
                    "ticker_sentiment_score": "0.037882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.044634",
                    "ticker_sentiment_score": "0.037882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.262994",
                    "ticker_sentiment_score": "0.038905",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug",
            "url": "https://www.cnbc.com/2024/03/08/novo-nordisk-ceo-weight-loss-pill-could-become-a-best-in-class-drug.html",
            "time_published": "20240308T173759",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107384880-17099162771709916274-33634235945-1080pnbcnews.jpg?v=1709916276&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.134685,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.09186",
                    "ticker_sentiment_score": "-0.110504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.270773",
                    "ticker_sentiment_score": "0.024796",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic or Tesla? Markets are in no doubt which is hotter | Business",
            "url": "https://www.cnn.com/2024/03/08/business/novo-nordisk-share-price-wegovy/index.html",
            "time_published": "20240308T162300",
            "authors": [
                "Anna Cooban"
            ],
            "summary": "Ozempic or Tesla? Markets are in no doubt which is hotter ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1812475431.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.034036,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "0.198439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.256179",
                    "ticker_sentiment_score": "-0.003894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNSKF",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "0.068617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.242631",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37562828/novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug",
            "time_published": "20240308T161201",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S's NVO head of development, Martin Holst Lange, expressed strong confidence in the drugmaker's ability to launch the pill version of its experimental weight loss drug, amycretin, within this decade. The optimism follows the announcement of robust early trial data.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-maker-Novo-Nordisk_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.178006,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.194242",
                    "ticker_sentiment_score": "-0.128504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.461283",
                    "ticker_sentiment_score": "0.416537",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Market Rally Hits Fresh Highs As Nvidia, Bitcoin Soar: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-hits-fresh-highs-as-nvidia-novo-nordisk-bitcoin-soar-weekly-review/",
            "time_published": "20240308T155800",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "The stock market rally suffered a sharp loss Tuesday but quickly rebounded, with the S&P 500 and Nasdaq composite hitting record highs. The Dow Jones fell modestly, but pared losses. Nvidia ( NVDA ) and chipmakers led the advance, while some software names struggled.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/STock-NYSEstockExchange-05-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.032056,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TGT",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.161391",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.095449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTLB",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.029991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "0.105246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.095245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.096651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "-0.011132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPS",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.102577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BASE",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.061438",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.082144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BURL",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.164906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SE",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.026943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.124593",
                    "ticker_sentiment_score": "-0.138354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.01093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.067953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JWN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.074982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MARA",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.073763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.165265",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.103957",
                    "ticker_sentiment_score": "-0.108494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.134097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVAV",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "-0.102717",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.114471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.164906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.102577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.123255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.103521",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.123255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.062488",
                    "ticker_sentiment_score": "-0.031232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.067571",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biogen Surges On A Setback For Lilly's Rival Alzheimer's Drug",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-lly-biogen-fda-alzheimers-drug/",
            "time_published": "20240308T150800",
            "authors": [
                "ALLISON GATLIN",
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Biogen Stock Surges After FDA Delays Its Decision On Eli Lilly's Alzheimer's Treatment Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.183058,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043108",
                    "ticker_sentiment_score": "0.132517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.043108",
                    "ticker_sentiment_score": "-0.048847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.050901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043108",
                    "ticker_sentiment_score": "0.442486",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.550804",
                    "ticker_sentiment_score": "0.204664",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Up on Upbeat Data From New Obesity Pill Study",
            "url": "https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study",
            "time_published": "20240308T150300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.190026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.256719",
                    "ticker_sentiment_score": "0.151479",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.256719",
                    "ticker_sentiment_score": "0.105076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.01855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.444487",
                    "ticker_sentiment_score": "0.34082",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7",
            "url": "https://www.businessinsider.com/weight-loss-drugs-pharmaceutical-companies-stocks-novo-eli-lilly-pfizer-2024-3",
            "time_published": "20240308T145900",
            "authors": [
                "Dan DeFrancesco"
            ],
            "summary": "Pharma companies are seeing stocks surge thanks to weight-loss drugs - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.096047,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.123229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.187403",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.063848",
                    "ticker_sentiment_score": "0.150511",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.063848",
                    "ticker_sentiment_score": "0.091059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.040483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMC",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.040483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063848",
                    "ticker_sentiment_score": "0.129424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.040483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.063848",
                    "ticker_sentiment_score": "0.042246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.085992",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Daily: TikTok Pop-Up Prompts Users To Call Congress Over Ban",
            "url": "https://www.forbes.com/sites/forbesdaily/2024/03/08/forbes-daily-tiktok-pop-up-prompts-users-to-call-congress-over-ban/",
            "time_published": "20240308T131947",
            "authors": [
                "Forbes Daily"
            ],
            "summary": "This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. Vegas oddsmakers would have you believe that the 96th Academy Awards on Sunday will be the Oppenheimer show.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65eb0ffd2d94b7a021f35e37/0x0.jpg?format=jpg&crop=4000,2251,x0,y154,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.100126,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MAT",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.163432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.015731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.000896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.052215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.038165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.106743",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.106743",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WSM",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.015731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.015731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.052215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IMAX",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.03806",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.000896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.015731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.14612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.132583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:LINK",
                    "relevance_score": "0.020045",
                    "ticker_sentiment_score": "0.132583",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Delays Decision On Eli Lilly's Alzheimer Drug",
            "url": "https://www.investors.com/news/technology/fda-delays-decision-on-eli-lillys-alzheimer-drug/",
            "time_published": "20240308T120800",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.235291,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.766141",
                    "ticker_sentiment_score": "-0.265067",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.199339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.614436",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "-0.317406",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Viking  ( VKTX )  Stock Down on Novo Nordisk's Obesity Pill Data",
            "url": "https://www.zacks.com/stock/news/2237803/viking-vktx-stock-down-on-novo-nordisks-obesity-pill-data",
            "time_published": "20240308T114700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.142303,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.220141",
                    "ticker_sentiment_score": "0.015164",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.543935",
                    "ticker_sentiment_score": "-0.052958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.220141",
                    "ticker_sentiment_score": "0.075149",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}